WO1993016176A1 - Immobilization of chemical species in crosslinked matrices - Google Patents

Immobilization of chemical species in crosslinked matrices Download PDF

Info

Publication number
WO1993016176A1
WO1993016176A1 PCT/US1993/001248 US9301248W WO9316176A1 WO 1993016176 A1 WO1993016176 A1 WO 1993016176A1 US 9301248 W US9301248 W US 9301248W WO 9316176 A1 WO9316176 A1 WO 9316176A1
Authority
WO
WIPO (PCT)
Prior art keywords
coupling compound
reactive groups
latent reactive
molecules
chemical specie
Prior art date
Application number
PCT/US1993/001248
Other languages
French (fr)
Inventor
Dale Gustaf Swan
Mark William Josephson
Melvin John Swanson
Original Assignee
Bio-Metric Systems, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio-Metric Systems, Inc. filed Critical Bio-Metric Systems, Inc.
Priority to CA002107683A priority Critical patent/CA2107683C/en
Priority to JP51429293A priority patent/JP3455217B2/en
Priority to AT93905897T priority patent/ATE192487T1/en
Priority to EP93905897A priority patent/EP0585436B1/en
Priority to DE69328523T priority patent/DE69328523T2/en
Publication of WO1993016176A1 publication Critical patent/WO1993016176A1/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0002Organic membrane manufacture
    • B01D67/0006Organic membrane manufacture by chemical reactions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0029Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081After-treatment of organic or inorganic membranes
    • B01D67/0093Chemical modification
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D67/00Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
    • B01D67/0081After-treatment of organic or inorganic membranes
    • B01D67/0093Chemical modification
    • B01D67/00931Chemical modification by introduction of specific groups after membrane formation, e.g. by grafting
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D69/00Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/14Dynamic membranes
    • B01D69/141Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D69/00Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
    • B01D69/14Dynamic membranes
    • B01D69/141Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes
    • B01D69/1411Heterogeneous membranes, e.g. containing dispersed material; Mixed matrix membranes containing dispersed material in a continuous matrix
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/28Polymers of vinyl aromatic compounds
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/28Polymers of vinyl aromatic compounds
    • B01D71/283Polyvinylpyridine
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/40Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/40Polymers of unsaturated acids or derivatives thereof, e.g. salts, amides, imides, nitriles, anhydrides, esters
    • B01D71/401Polymers based on the polymerisation of acrylic acid, e.g. polyacrylate
    • B01D71/4011Polymethylmethacrylate
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/44Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/44Polymers obtained by reactions only involving carbon-to-carbon unsaturated bonds, not provided for in a single one of groups B01D71/26-B01D71/42
    • B01D71/441Polyvinylpyrrolidone
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/52Polyethers
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D71/00Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
    • B01D71/06Organic material
    • B01D71/52Polyethers
    • B01D71/521Aliphatic polyethers
    • B01D71/5211Polyethylene glycol or polyethyleneoxide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C12N11/087Acrylic polymers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23Carbohydrates
    • A61L2300/232Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404Biocides, antimicrobial agents, antiseptic agents
    • A61L2300/406Antibiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/42Anti-thrombotic agents, anticoagulants, anti-platelet agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45Mixtures of two or more drugs, e.g. synergistic mixtures
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2323/00Details relating to membrane preparation
    • B01D2323/30Cross-linking
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2323/00Details relating to membrane preparation
    • B01D2323/34Use of radiation
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2325/00Details relating to properties of membranes
    • B01D2325/14Membrane materials having negatively charged functional groups
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2325/00Details relating to properties of membranes
    • B01D2325/16Membrane materials having positively charged functional groups
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2325/00Details relating to properties of membranes
    • B01D2325/36Hydrophilic membranes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D2325/00Details relating to properties of membranes
    • B01D2325/38Hydrophobic membranes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813Carrier is a saccharide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/816Attached to the carrier via a bridging agent
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815Carrier is a synthetic polymer
    • Y10S530/817Entrapped within the carrier, e.g. gel, hollow fibre

Definitions

  • U.S. patent 4,716,122 (Sheefers) refers to the use of a heterobifunctional photoactivatable compound, one functional group being an aryl azide and the other being an N-hydroxysuccinimide ester to bind an antibody or other protein to a solid surface.
  • U.S. patent 3,959,078 refers to the bonding of enzymes to a surface using a chemical linker employing an aryl azide photochemical group.
  • U.S. patent 4,007,089 (Smith III) teaches bonding a biologically active compound to a surface through a bifunctional linking compound by first attaching that compound to a surface via a phenyl azide group and then attaching the linking compound to the biologically active compound through an s-triazine group.
  • U.S. patent 5,024,742 (Nesburn et al) teaches a method of crosslinking collagen molecules to themselves or to other surfaces using a heterobifunctional reagent.
  • a photoreactive group or other latent reactive group usually is first attached to the chemical specie and thereafter is activated to cause covalent bonding to the solid surface.
  • procedures of this type have been quite successful, it has been necessary to manufacture latent reactive group-containing derivatives of each of the chemical species that one wishes to covalently bond to a surface.
  • heparin may be photoderivatized as taught in International
  • the method of the invention involves bringing together in covalent bonding proximity a desired chemical specie and a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to another coupling compound molecule or to the chemical specie.
  • the method involves simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other.
  • a film comprising the coupling compound and the chemical specie is formed upon a surface, as by coating the surface with a solution containing the coupling compound and the chemical specie.
  • latent reactive groups carried by the polymeric coupling compound form covalent bonds to the surface, thereby co-immobilizing the coupling
  • the surface may be a liquid surface or a surface to which the latent reactive groups do not readily form covalent bonds, and the completed film with its three dimensional, crosslinked structure may be removed from the surface for use elsewhere as, for example, a protective wound dressing.
  • the method of the invention involves forming on a surface a coating of the chemical specie that is desired together with and in covalent bonding proximity to a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to a coupling compound molecule (either the same or different), to the chemical specie, or to the surface.
  • the method involves simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other and to the surface.
  • the polymeric coupling compound contains an average of at least two latent reactive groups per molecule. Preferably, the average number of such groups per 100 Angstroms extended chain length ranges from 0.05 to 12 and preferably from 0.2 to 2.
  • the coupling compound desirably is formed or derived from a synthetic polymer, although coupling compounds derived from natural polymers also may be employed. DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • the coupling compounds employed in the present invention are polymeric in nature; that is, they have repeating units and a molecular weight distribution. Most preferably, the coupling compounds are derived from or formed as synthetic polymers.
  • the polymers of the invention include oligomers, homopolymers and copolymers resulting from addition or condensation polymerization, and natural polymers including nucleic acids, oligosaccharides, linear polysaccharides such as amylose, dextran, chitosan, heparin and hyaluronic acid, and branched polysaccharides such as amylopectin, glycogen and hemi-celluloses.
  • the polymers may include several distinct polymer types, as may be prepared by terminal or side chain grafting.
  • the polymers of the invention may include cellulose-based products such as hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, nitrocellulose, cellulose acetate and cellulose butyrate, acrylics such as those polymerized from hydroxyethyl acrylate, hydroxyethyl methacrylate, glyceryl acrylate, glyceryl methacrylate, acrylic acid, methacrylic acid, acrylamide and methacrylamide, vinyls such as polyvinyl pyrrolidone and polyvinyl alcohol, nylons such as polycaprolactam, polylauryl lactam, polyhexamethylene adipamide and polyhexamethylene dodecanediamide, polyurethanes and polylactic acids. Of particular importance are the vinyl polymers such as polyvinyl pyrrolidone and
  • polyacrylamide and the polyethers such as polyethylene glycol.
  • the invention is described below primarily with respect to the use of single coupling compounds that are homopoly functional (that is, that bear two or more identical latent reactive groups (and such is preferred)).
  • the coupling compounds themselves may be heteropolyfunctional (that is, they may contain two or more different latent reactive groups) and they may have different properties which they confer upon the matrix.
  • the polymeric coupling compounds employed in the invention desirably are soluble or at least dispersible in a solvent (to form, for example, a colloidal suspension), and preferably are soluble in water to at least the extent of 1 gram/1 at 23 °C.
  • the polymers of the invention desirably have extended chain lengths of at least about 45 Angstroms, and preferably at least about 1000 Angstroms.
  • Extended Chain Length refers to theoretical straight line lengths measured along the backbone of a polymeric coupling compound, assuming that the polymer chain is stretched out to its maximum length consistent with observing proper bond angles between adjacent atoms.
  • polyethylene -(CH.rCH ⁇ -, exhibits an "extended” chain length between alternate carbon atoms of about 2.5 A (observing a bond angle of 109.5°), although the sum of the (carbon-carbon) bond distances along the molecule between alternate
  • carbon atoms is about 3.06 A.
  • Latent reactive groups are groups which respond to specific applied external stimuli to undergo active specie generation with resultant covalent bonding to an adjacent chemical structure, e.g., an adjacent same or different molecule.
  • Latent reactive groups are those groups of atoms in a molecule which retain their covalent bonds unchanged under conditions of storage but which, upon activation by an external energy source, form covalent bonds with other molecules.
  • the latent reactive groups generate active species such as free radicals and particularly nitrenes, carbenes, and excited states of ketones upon absorption of external electric, electromagnetic or kinetic (thermal) energy.
  • Latent reactive groups may be chosen to be responsive to various portions of the electromagnetic spectrum, and latent reactive groups that are responsive to e.g., ultraviolet and visible portions of the spectrum are preferred and are referred to herein occasionally as "photochemical" groups. Latent reactive groups as described are generally well known.
  • the azides constitute a preferred class of latent reactive groups and include arylazides ( N 3 ) such as phenyl azide and particularly 4-fluoro-3-nitrophenyl azide, acyl azides
  • N 3 such as ethyl azidoformate, phenyl azidoformate, sulfonyl azides (-S-N 3 ) such as benzenesulfonyl azide, and phosphoryl azides (RO) 2 P-N 3 such as diphenyl phosphoryl azide and diethyl phosphoryl azide.
  • Diazo compounds constitute another class of latent reactive groups and include diazoalkanes (-CHN 2 ) such as diazomethane and diphenyldiazomethane, diazoketones (-C-CHN ⁇ such as diazoacetophenone and l-trifluoromethyl-l-diazo-2-pentanone, diazoacetates (-0-C- CHN ⁇ such as t-butyl diazoacetate and phenyl diasoacetate, and beta-keto-alpha- diazoacetates (-C-C-C-0-) such as t-butyl alpha diazoacetoacetate.
  • diazoalkanes -CHN 2
  • diazoketones such as diazoacetophenone and l-trifluoromethyl-l-diazo-2-pentanone
  • diazoacetates -0-C- CHN ⁇ such as t-butyl diazoacetate and phenyl diasoacetate
  • Photoactivatable aryl ketones such as bensophenone and acetophenone are of particular importance inasmuch as these groups are subject to multiple reactivation in water and hence
  • Peroxy compounds are contemplated as another class of latent reactive groups and include dialkyl peroxides such as di-t- butyl peroxide and dicyclohexyl peroxide and diacyl peroxides such as dibenzoyl peroxide and diacetyl peroxide and peroxyesters such as ethyl peroxybenzoate.
  • the coupling compounds Upon activation of the latent reactive groups, the coupling compounds are covalent'y bound to coupling compound molecules and to chemical species (and, in the preferred embodiment, to the surfaces to which the chemical species are to be co-immobilized), by covalent bonds through residues of the latent reactive groups.
  • latent reactive groups are as follows: Latent Reactive Group Residue Functionality aryl asides amine
  • R-NH-R' acyl asides amide
  • R-O-C-NH-R' sulfonyl asides sulfonamide
  • R-S-NH-R' phosphoryl asides phosphoramide (RO ⁇ -NH-R' diasoalkanes new C-C bond diazoketones new CC bond & ketone diasoacetates new C-C bond & ester beta-keto-alpha-diazoacetates new CC bond & B-ketoester aliphatic azo new C-C bond diazirines new C-C bond ketenes new C-C bond photoactivated ketones new C-C bond & alcohol dialkyl peroxides ethers diacyl peroxides esters & new CC bonds
  • Three- dimensional molecular networks may be formed through the use of polymeric coupling compound molecules each having two or more latent reactive groups, and in general the density of covalent bonds resulting from activation of the reactive groups and hence the "tightness" of the three-dimensional molecular network that is formed will be increased by decreasing the distance between latent reactive groups that are employed in the coupler compound.
  • a bifunctional polymeric coupling compound may have one latent reactive group at each of its two ends.
  • 4-bromomethylbenzophenone derived from the free radical bromination of 4-methylbensophenone
  • polyethylene glycol may be reacted with polyethylene glycol to form a bifunctional coupling compound having -(CH 2 -CH 2 - 0)- repeating units and terminating in benzophenone latent reactive groups.
  • Polymeric coupling compounds used in the invention may have latent reactive groups incorporated at random positions along the polymer backbone. It
  • polymeric coupling compounds desirably, but not necessarily, have latent reactive groups at their ends or at random locations along their backbones (spaced from their ends) or both.
  • backbone as used herein in connection with polymer molecules, reference is made to the chain of atoms that is characteristic of the polymer and that results from the polymerization reaction.
  • polyethylene glycol polymers are characterized by a "backbone" of repeating -(-
  • polyacrylamide and polyvinyl pyrrolidone have backbones characterized by carbon-carbon bonds, alternating carbon atoms in the backbone having pendent amide or pyrrolidone groups, respectively.
  • a polymer that includes at least one latent reactive group along its backbone spaced from its ends can be prepared by copolymerizing the basic monomer or monomers for the polymer with a monomer to which can be readily attached a latent reactive group such as a photoreactive group.
  • a photoreactive polyacrylamide polymer can be obtained by copolymerizing acrylamide with a small quantity of N-(3-aminopropyl)methacrylamide to provide random amine-functional groups along the polymer backbone, and then reacting the polymer with an amine-reactive photoreactive reagent such as benzoylbenzoylchloride. Coupling compounds may be derived from naturally
  • the polymeric coupling compounds employed in the present invention desirably carry a sufficient number of latent reactive groups so that the average number of latent reactive groups per 100 Angstrom extended chain length ranges from 0.05 to 12 and preferably from 0.2 to 2.
  • the chemical species which can be co-immobilized together with the coupling compound in a three dimensional network according to the invention may be chosen from a wide variety of suitable substances.
  • the chemical species used herein preferably are free of latent reactive groups of the type carried by the coupling compounds, that is, latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compounds during the activation step.
  • latent reactive groups of the type carried by the coupling compounds
  • two or more chemical species may be employed, each lending to the matrix its particular properties. For example, it may be desired to immobilize at the same time an anticoagulant such as heparin, a thrombolytic agent such as streptokinase and, if desired, a protease inhibitor.
  • Synthetic Polymers Sulfonic acid-substituted Lubricity, negatively charged surface polyacrylamide Polyacrylamide Lubricity, protein repulsion Polyethylene glycol Lubricity, cell and protein repulsion Polyethyleneimine Positively charged surface Polylactic acid Negatively charged surface Polyvinyl alcohol Lubricity Polyvinyl pyrrolidone Lubricity Quaternary amine-substituted Lubricity, positively charged surface polyacrylamide Silicones Lubricity Conductive polymers (e.g., Electric conductivity polyvinylpyridine polyacetylene, polypyrrole
  • Phospholipids Hydrophobicity, lubricity, biodegradable fatty acid source Hydrophobicity, lubricity, biodegradable fatty acid source
  • nucleosides Source of purines, pyrimidines, enzyme cofactors
  • Drugs/vitamins/cofactors Enzyme cofactors Immobilized enzymes Heme compounds Globin binding/surface oxygenation Drugs Drug activity
  • Dyes e.g., azo dyestuffs
  • Coloring agents Fluorescent compounds Fluorescence
  • the product that is formed via activation of the latent reactive groups carried by the coupling compound is an insoluble, three dimensional crosslinked matrix that is desirably in solid or at least semi-solid (e.g., gel) form and that exhibits the properties of the chemical specie(s) incorporated in it, or properties of the coupling compound(s), or both.
  • the coupling compound may be a polymer that itself provides the matrix with valuable properties; for example, use of a photo- derivatized polyvinylpyrrolidone may confer slipperiness and water wettability to the matrix.
  • Both the coupling compound and the chemical specie may provide the matrix with desired properties.
  • a matrix formed from photopolyacrylamide as the polymeric coupling compound and heparin as the chemical specie may exhibit a reduction in protein abso ⁇ tion characteristic of the polyacrylamide and the antithrombogenic activity characteristic of heparin.
  • the matrices may be in the form of fibers, beads or other particles (for use, for example, in chromatographic columns), or in the form of free-flowing or non-flowing gels.
  • the matrices preferably are in the form of films which may be continuous or discontinuous and which may have thicknesses ranging from a few nanometers up to a millimeter or more.
  • a film may be self supporting, as when in sheet or tubing form; it may be in the form of a coating formed on and supported by a surface and in its most preferred form covalently bonded to the surface.
  • the crosslink density of the three-dimensional polymeric network that is
  • bonds being formed per unit length measured along the extended backbone of the polymer or per unit of molecular weight of the polymer, and the resulting three- dimensional network will be more open; that is, it will have a larger effective pore size.
  • the use of polymeric coupling compounds having a greater number of latent reactive groups, or, for that matter, having latent reactive groups concentrated along a certain portion of the molecule, will provide a more tightly crosslinked, dense three-dimensional matrix.
  • the tightness of the three-dimensional network that is formed will depend upon the density of covalent bonds formed from the latent reactive groups carried by the coupling compound and this, in turn, depends upon the number of latent reactive groups per molecule of the coupling compound and the relative amounts of coupling compound and chemical specie that are employed.
  • the ability of the polymeric coupling compound to become extended in solution also contributes to the loftiness or openness of the three dimensional network, and polymeric coupling compounds that are soluble to the extent of at least about 1 g/1 in water are preferred.
  • the three-dimensional network that is formed in accordance with the method of the invention not only has utility in providing the resulting film with characteristics of the co-immobilized chemical specie, but also has utility in that it can be used to capture free chemical species (chemical species not covalently bound to a coupling compound molecule) so that the matrix, when in contact with a suitable liquid medium such as an aqueous solution, may gradually release the
  • the quantity of chemical specie that is thus released by the three-dimensional polymer network and the rate of release may depend upon a number of factors, including the loftiness or openness of the three- dimensional network, the amount of the free chemical specie that is employed, and the degree of affinity or repulsion between the three-dimensional network and the chemical specie.
  • the polymeric coupling compound and the chemical specie exhibit an affinity permitting them in solution to assume a preferred orientation with respect to each other prior to activation of the latent
  • the affinity of the coupling compound and the chemical specie may involve the hydrophobic or hydrophilic characteristics of these compounds, e.g., in which hydrophobic portions of these compounds preferentially orient next to each other.
  • the affinity between the coupling compound and the chemical specie may involve ionic attraction between portions of the molecules.
  • the polymeric coupling compound may be polyionic and the chemical specie also may be ionic, the coupling compound having a net charge opposite the net charge of the chemical specie.
  • the coupling compound may be a vinyl copolymer containing aminopropyl pendent groups resulting from the use of an aminopropylmethacrylate monomer, the coupling compound thus having a net positive charge.
  • the chemical specie may be a dextran sulfate having a net negative charge.
  • Free chemical species may be positioned or entrapped within the three- dimensional network that is formed by being present during formation of the network or by being added after the network has been formed.
  • the chemical specie By employing a large amount of the chemical specie in comparison to the coupling compound, one may ensure that at least some of the chemical specie will not become covalently bound to the coupler, and the resulting free chemical specie may thus become physically entrapped within the network, and some may be slowly released.
  • additional chemical specie may be inco ⁇ orated in the network by replacing the solvent that is present in the network with a solvent solution containing the chemical species.
  • solvent may be removed from a film that is initially formed, and the dried film may then be contacted with a solution of an additional quantity of the same or a different chemical species, causing molecules of the chemical species to enter the network and to become trapped therein upon removal of the solvent in a subsequent drying procedure.
  • the resulting films when placed in contact with a liquid medium such as blood or an open wound containing serous fluid, will release molecules of the free chemical species into the blood or serous fluid, the amount and rapidity of the release of the chemical agent depending upon how readily the chemical species can migrate from the coating into the blood or serous fluid, and, of course, upon the concentration gradients of the chemical species that are established.
  • the remaining film will yet retain molecules of the chemical species covalently bonded to it such that it will continue to itself exhibit characteristics of the chemical species.
  • heparin may be co-immobilized with a photoderivatised polyacrylamide coupling compound upon a surface, the process making use of a large amount of heparin so that some of the heparin is not covalently bonded to the polyacrylamide.
  • the resulting film when brought into contact with blood, releases heparin into the blood at a decreasing rate over a period of time. Once all of the available free heparin has escaped from the surface of the film into the blood, the heparin molecules that are covalently bound to the surface will continue to provide the surface with the antithrombogenic characteristics of heparin, If desired, the three-dimensional network that is formed may be chosen to be subject to destruction in use.
  • the network may include ester linkages that are cleavable by the esterases in blood issuing from a wound.
  • a protective coating may be made from a vinyl polymer coupling compound containing aminoethylmethacrylate mere units to which latent reactive groups are coupled and a biologically active chemical species such as heparin.
  • the coating may slowly degrade when in contact with blood due to hydrolysis of the ester bonds by esterases in the blood.
  • chemical species containing heparin and having the antithrombogenic properties of heparin may be slowly released.
  • free molecules of other chemical species that is, molecules not covalentiy bound to the coupling compound
  • photopolyacrylamide and heparin may be co-immobilized on a surface, and an
  • antibiotic such as cephalosporin or vancomycin may be inco ⁇ orated in the matrix.
  • the antibiotic Upon contact with blood, the antibiotic is released gradually by being leached from the surface, leaving behind a heparinized surface.
  • Different free molecules of various chemical species may be inco ⁇ orated in a single matrix in this manner.
  • several antibiotics may be employed which exhibit activity against different microorganisms, or which provide more effective control over a single microorganism. If it is desired to form the film upon a surface to which the film is covalentiy bonded as it is formed, then the latent reactive groups that are employed are preferably attracted to the surface to be coated so that the latent reactive groups will readily come into covalent bonding proximity with the surface.
  • Photochemical groups such as the aryl asides and the aromatic ketones commonly are relatively hydrophobic, as are many of the solid surfaces (e.g., polystyrene, polysulfone arid polyolefin) that may be coated in accordance with the invention.
  • Hydrophilic compounds are usually relatively polar and often are ionizable. Such compounds usually bind water molecules strongly.
  • Hydrophobic compounds are usually relatively non-polar and non-ionizing. Hydrophobic surfaces will generally cause water molecules to structure in an ice ⁇ like conformation at or near the surface.
  • Hydrophobic and hydrophilic are relative terms, of course, and are used herein in the sense that various compositions, liquids and surfaces may be hydrophobic or hydrophilic relative to one another.
  • a discourse on the subject is found in Hoffman, Letter to the Editor: A general classification scheme for “hydrophilic” and “hydrophobic” biomaterial surfaces. J. Biol. Mat. Res. 20,pp. ix-xi (1986).
  • Crosslinked, three-dimensional matrix films of co-immobilized coupling compound and chemical species can be produced by combining the polymeric coupling compound and chemical species precursors in solution and then physically forming the solution into a sheet or film configuration before activating the latent reactive groups.
  • an aqueous solution of the precursors may be floated upon the surface of a non-miscible liquid such as a perfluorocarbon liquid.
  • the film After activating the latent reactive groups of the polymeric coupling compound, the film, which may at this point be self-supporting, may be removed from the liquid surface.
  • this process may be performed on a continuous basis if desired, the precursor solution being sheeted onto a bath of the non-miscible liquid at one end of the bath, and the continuous self-supporting film being removed from the other end of the bath.
  • the surface upon which the film is physically formed may be a solid surface such as polytetrafluoroethylene to which the latent reactive groups, when activated, do not readily bond and from which the film may be removed.
  • the method of the invention finds particular utility, however, in the formation of a film upon a surface, desirably a solid surface, to which the film becomes covalently bonded by latent reactive groups of the coupling compound.
  • the surface itself becomes chemically involved in the formation of the three-dimensional matrix.
  • Such surfaces preferably have abstractable hydrogen atoms and participate readily in the formation of covalent bonds upon activation of the latent reactive groups.
  • selected chemical specie are applied to a surface, and the latent reactive groups of the coupling compounds are simultaneously reacted to form covalent bonds between the chemical specie and the coupling compound, between the coupling compound and the surface, and between different molecules of the coupling compound, to form a three dimensional molecular network.
  • the coupling compound and the chemical specie may be combined and partially pre-reacted before they are applied to the surface.
  • the polymeric coupling compound and the chemical specie are applied to a surface from a solvent medium, preferably from solution and most preferably from aqueous solution.
  • the coupling compound and the chemical specie are combined in solution and applied as a wet film to the surface, following which the latent reactive groups are activated, by light, in the case of photoreactive groups.
  • Solvent may be partially or totally removed from the wet film before activation of the latent reactive groups.
  • the latent reactive groups may be reacted in the presence of the solvent.
  • the coupling compound and the chemical specie may be applied to the surface as separate, wet films which blend or interdiffuse together to bring the coupling compound and the chemical specie into covalent bonding proximity, and it is contemplated that the first wet film may be at least partially dried before application of the second film.
  • the "surface" upon which may be formed a film according to the invention is defined by the interface between distinct phases of compositions, the solid surface of a tangible object such as a sheet of material being perhaps the most commonly thought of surface and being defined by a gas- solid interface.
  • Surfaces may be defined by the interface between liquid and solid compositions as exemplified by the solid surface of solid particles in suspension, by the interface between immiscible liquids as exemplified by emulsions, and by gas-liquid interfaces as exemplified by the surface of a liquid bath.
  • a solid surface as referred to herein is a tangible surface defined by the interface between solid phase materials (including soft gels) and gas or liquid phases. Specific examples include the surfaces of medical devices such as blood bags, catheters, bone and tissue prostheses, and living bone and tissue surfaces. Other solid surfaces are exemplified as the surfaces of membranes, fibers such as hollow fibers employed in chemical reactors and fibers employed in structural composites, and chromatographic media particles and the like.
  • Polyethyleneglycol Ether (BBE-PEG(3350)-BBE) To 100 g of polyethylene glycol 3350 (PEG(3350)) in a 1 liter round bottom flask was added 400 ml of toluene. The toluene was evaporated off to remove moisture. The PEG was then dissolved in tetrahydrofuran (250 ml) by stirring at reflux temperatures under an argon atmosphere, and the solution was allowed to cool. To the solution was added NaH (2.3 g) and the solution was stirred for an hour, after which 20.5 g of bromomethylbenzophenone was added.
  • Acrylamide (10.24 g) was dissolved in 200 ml of deionized water. To the solution was added 0.279 mg of N-(3-aminopropyl)methacrylamide, 0.33 g of ammonium persulfate and 0.155 g of N ⁇ NSN'-tetramethylethylenediamine. The solution was evacuated in a filter flask with a water aspirator for 10 minutes. The tubing was clamped and the solution left under vacuum for one hour. The resulting polymer solution was dialyzed against deionized water. To 150 ml of polymer solution in a PTFE bottle containing 3.0 g of polymer was added 0.504 ml of triethylamine.
  • EXAMPLE 3 Co-immobilization of Polyvinylpyrrolidone 1.0 gm of polyvinylpyrrolidone (PVP) having a number average molecular weight of about 360,000 was dissolved in 25ml of water. 350 mg of BBE- PEG(3350)-BBE prepared as in Example 1 were dissolved in 25 ml of water. The solutions were mixed and lyophilized.
  • PVP polyvinylpyrrolidone
  • Heparin was dissolved at 3 mg/ml in an aqueous solution of photo PAA prepared as in Example 2 at 3 mg/ml for subsequent co-immobilization on membrane surfaces.
  • Another aqueous solution was prepared by dissolving heparin at 6 mg/ml in photo PAA at 3 mg/ml.
  • a photoreactive derivative of heparin was prepared by reacting heparin with benzoyl-benzoyl-epsilon- aminocaproyl-N-oxysuccinimide in dimethylsulfoxide/carbonate buffer, pH 9.0. The solvent was evaporated and the photoheparin was dialyzed vs. water, and lyophilized, and then dissolved in water at 3 mg/ml.
  • Heparin was also dissolved in water at 3 mg/ml for subsequent abso ⁇ tion onto membrane surfaces. Each solution was applied to specimens of regenerated cellulose membranes by soaking overnight at 37°C. The membranes were then dried and UV illuminated in a N 2 atmosphere for 2 minutes. The membranes were then washed four times for three minutes each in an ultrasonic bath of 0.5% Tween 20 in phosphate buffered saline
  • Photo PAA was prepared as follows: To 2 grams of N-(3-aminopropyl)methacrylamide (APMA) in 80 ml of dry dimethylsulfoxide was added 4.96 gm of 4-bensoylbenzoyl-epsilon- aminocaproyl-N-oxysuccinimide and 2.26 ml of N,N,N'N'- tetramethylethylenediamine. The solution was stirred for four hours, after which 20 gm of acrylamide in 286 ml of DMSO and 300 mg of azobis(isobutyronitrile) in 100 ml of DMSO were added. The solution was bubbled with helium for 5 minutes, after which the space above the solution was filled with argon.
  • APMA N-(3-aminopropyl)methacrylamide
  • APMA N-(3-aminopropyl)methacrylamide
  • APMA N-(3-aminopropyl)methacrylamide
  • Polymerization was allowed to occur at 55°C for 24 hours.
  • the polymer was then precipitated in ethanol, redissolved in 250 ml of deionized water, and dialyzed vs. water. Insoluble material was removed by filtration, and the clear solution was lyophilized.
  • PTFE membranes were first prewetted with methanol and then were soaked for 4 hours in an aqueous solution (5 mg/ml) of the photo PAA prepared above. The coatings then were illuminated with UV light for 3 minutes and washed in PBS. Native bovine skin collagen (containing types I and III) at 1.25 mg/ml was dialyzed vs. 3 mM HC1, and the photo PAA prepared as above was dissolved in the collagen solution at 5 mg/ml. Porous PTFE membranes that previously had been coated with photo PAA and irradiated were then soaked in the solution for 4 hours at 4°C. The membranes were illuminated with UV light for 3 minutes, after which they were washed extensively with PBS and air dried.
  • Polyethylene tubing was filled with a solution containing 2.5 mg/ml photo PAA prepared as in Example 5 and 2.5 mg/ml streptokinase, after which the tubing was UV illuminated for 8 minutes. After rinsing the tubing by circulating
  • streptokinase activity was detected in the tubing by adding plasminogen (0.5 units/ml) and D-val-leu-lys-p-nitroanilide and measuring at 405 nm the color generated by release of p-nitroaniline.
  • Photo PAA as prepared in Example 2, and heparin are co-immobilized upon a surface as described in Example 7.
  • the immobilized polyacrylamide-heparin matrix is placed overnight in an aqueous solution containing 100 mg/ml of vancomycin. The tubing is removed and air-dried. Upon subsequent blood contact with the tubing, the antibiotic is released from the photo PAA-heparin hydrogel at a gradually decreasing rate. Complete release of the matrix-adsorbed drug leaves a biocompatible heparinized, hydrogel surface.
  • EXAMPLE 9 Preparation of Co-immobilized Photo PAA/Hyaluronic Acid
  • the mono benzoylbensyl ether of polyethylene glycol (BBE-PEG-OH) was synthesized using polyethylene glycol (HO-PEG-OH) by the following procedure: To polyethylene glycol (20 g, mol. wt. 8000) dissolved in 100 ml of dry tetrahydrofuran (THF) was added 60 mg of NaH followed by stirring under a
  • a mixture of equal weights of BBE-PEG-OH, HO-PEG-OH and the BBE- PEG-BBE of Example 1 was dissolved at 0.5 mg/ml in a 50% isopropanol solution in water.
  • Commercially available porous polycarbonate membranes were soaked in the resulting solution for 10 minutes and were dried in a cold air stream for 3 minutes. The membranes were exposed to UV radiation for 10 seconds, and then were washed in water for 15 minutes and air dried.
  • the wettability of the membranes, as measured by the ease with which an aqueous solution passes through them, was tested by measuring the time required to pass 500 ml of water through 47 mm diameter discs under a pressure drop across the discs of 625 mm Hg.
  • N-(3-aminopropyl)methacrylamide was added 102 mg of benzoylbenzoyl-epsilon-aminocaproyl-N- oxysuccinimide and 40 ul of NjNjN'N'-tetramethylethylenediamine.
  • the solution was stirred overnight, after which 1.0 gm of N- acryloyltris(hydroxymethyl)aminomethane in 5 ml of DMSO and 50 mg of azobis(isobutyronitrile) in 5 ml of DMSO were added.
  • the solution was bubbled with nitrogen for 5 minutes, sealed and stored at 55°C overnight.
  • the resulting polymer was precipitated in ethanol, redissolved in 10 ml of deionized water, dialyzed vs. water and lyophilized.
  • EXAMPLE 12 Coimmobilization of Dextran Sulfate onto Polystyrene Beads for Purifying Clotting Factors from Blood.
  • the ionic polymer prepared in Example 11 and the photo PAA prepared as in Example 5 were each dissolved in deionized water at 5 mg/ml.
  • dextran sulfate average molecular weight of 500,000 was added at 10 mg/ml.
  • These solutions were incubated with polystyrene beads (297-1000 urn diameter) for 24 hours at room temperature with mixing. The beads were then filtered to remove coating solutions and air dried. The beads were then spread into thin layers on aluminum foil, illuminated with UV light for 1.5 minutes, shaken, and illuminated for an additional 1.5 minutes.

Abstract

A method of immobilizing a chemical specie in a three-dimensional, crosslinked matrix. The method involves bringing together in covalent bonding proximity a desired chemical specie and a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable when activated of covalently bonding to another coupling compound molecule or to the chemical specie. The chemical specie desirably is free of latent reactive groups that are activated upon activation of the latent reactive groups are simultaneously activated to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other. Preferably, the three-dimensional matrix is formed as a coating upon a surface to which covalent bonds are formed upon activation of the latent reactive groups of the coupling compound.

Description

IMMOBILIZATION OF CHEMICAL SPECIES IN CROSSLINKED MATRICES
BACKGROUND OF THE INVENTION
It is often desirable to provide products such as catheters, blood bags, chromatography media, membranes, cell culture ware and the like with surfaces which have particular, predetermined characteristics. For example, it may be desirable to provide guide wires and catheters with external surfaces that permit them to slide easily within the vascular system of a human or other animal. It may be appropriate to provide the surfaces of prostheses that are to be implanted within the body with growth factors or similar chemical species that may contribute to the rapid proliferation of tissue on the prosthesis or, to the contrary, with chemical species for the purpose of preventing ongrowth of tissue. Some devices such as artificial eyes desirably have surfaces that are wettable and lubricous to the touch and that hence are comfortably received within the eye socket. Poorly adherent surfaces, as of certain polymers, may be treated to improve adhesive characteristics. Blood bags and other tubes which may come into contact with blood may be treated with hemocompatible agents such as heparin or a heparin derivative. Bandages or other devices which come into contact with wounds may have surfaces that are provided with antibiotic materials. Various diagnostic tests may involve test protocols in which antibodies or antigens are covalently immobilized upon a surface.
U.S. patent 4,716,122 (Sheefers) refers to the use of a heterobifunctional photoactivatable compound, one functional group being an aryl azide and the other being an N-hydroxysuccinimide ester to bind an antibody or other protein to a solid surface.
A series of papers by Guire, et al describes the use of polyfunctional photoderivatives of glucose oxidase and catalase in association with concanavalin A and glucose oxidase, respectively: Guire et al, Stepwise-Crosslinking Reagents for Photocoupling of Enzymes and Lectins to Mammalian Cells. Glycoconjugate
Research II, pp. 1051-1054, (1979); Guire et al, Stepwise Thermophotochemical
Crosslinking for Enzyme Stabilization and Immobilization: Enzyme Engineering 3, pp. 63-70 (1978); and Guire et al, Photochemical Coupling of Enzymes to Mammalian Cells. Pharmacological Research Communications, 9, No. 2, pp 131-
141 (1977).
U.S. patent 4,979,959 (Guire) refers to a biocompatible device in which various molecules such as cell attachment factors are covalently bonded to a solid surface through a chemical linking moiety. International Application No. PCT/US88/04487 published February 8, 1990
(Guire et al) refers to the bonding of various polymeric species to a solid surface through the use of latent reactive groups.
U.S. patent 3,959,078 (Guire) refers to the bonding of enzymes to a surface using a chemical linker employing an aryl azide photochemical group. U.S. patent 4,007,089 (Smith III) teaches bonding a biologically active compound to a surface through a bifunctional linking compound by first attaching that compound to a surface via a phenyl azide group and then attaching the linking compound to the biologically active compound through an s-triazine group. U.S. patent 5,024,742 (Nesburn et al) teaches a method of crosslinking collagen molecules to themselves or to other surfaces using a heterobifunctional reagent.
To covalently bond a specific chemical specie to a surface through
photoactivation, a photoreactive group or other latent reactive group usually is first attached to the chemical specie and thereafter is activated to cause covalent bonding to the solid surface. Although procedures of this type have been quite successful, it has been necessary to manufacture latent reactive group-containing derivatives of each of the chemical species that one wishes to covalently bond to a surface. For example, heparin may be photoderivatized as taught in International
Application No. PCT/US 88/04487 published February 8, 1990 and may be applied to various devices that come into contact with blood such as blood bags, tubes, and the like. However, the synthesis of latent reactive group-containing derivatives of various chemical species can be very expensive, both from the standpoint of developing the protocol for the synthesis of the derivative and also with respect to the manufacture of commercial quantities of the derivative.
It is also possible to attach desired chemicals to a surface by first providing the surface with latent reactive groups, then bringing the desired molecules into bonding association with the latent reactive groups, and activating the latent
reactive groups to cause the formation of covalent bonds. Reference is made particularly to U.S. Patent 4,722,906 (Guire). The method of this patent is dependent upon the ability of the target molecules to diffuse into bonding association with the latent reactive groups carried by the solid surface, however, and is highly selective of the target molecules that are to be attached. BRIEF DESCRIPTION OF THE INVENTION
It has now been found that a wide variety of chemical species such as heparin, growth factors, natural and synthetic polymers and the like may be covalently immobilized in an insoluble, three dimensional, crosslinked matrix, preferably in solid or semi-solid form and most preferably in film form, utilizing a polymeric coupling compound having latent reactive groups. The invention avoids the necessity of synthesizing latent reactive group derivatives of the various chemical species, and provides a three dimensional matrix which exhibits properties of the chemical specie, the coupling compound or both. Speaking broadly, the method of the invention involves bringing together in covalent bonding proximity a desired chemical specie and a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to another coupling compound molecule or to the chemical specie. The method involves simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other.
Preferably, a film comprising the coupling compound and the chemical specie is formed upon a surface, as by coating the surface with a solution containing the coupling compound and the chemical specie. In the most preferred embodiment, latent reactive groups carried by the polymeric coupling compound form covalent bonds to the surface, thereby co-immobilizing the coupling
compound and the chemical specie to the surface. If desired, the surface may be a liquid surface or a surface to which the latent reactive groups do not readily form covalent bonds, and the completed film with its three dimensional, crosslinked structure may be removed from the surface for use elsewhere as, for example, a protective wound dressing.
Thus, in the preferred embodiment, the method of the invention involves forming on a surface a coating of the chemical specie that is desired together with and in covalent bonding proximity to a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to a coupling compound molecule (either the same or different), to the chemical specie, or to the surface. The method involves simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other and to the surface.
The covalent bones between the chemical specie and the coupling compound, between the coupling compound and the surface, and between different
molecules of the coupling compound, form simultaneously, that is, during the same step. Thus, the chemical specie and the coupling compound are co- immobilized upon the surface. By judicious choice of the type and quantity of the coupling compound relative to the chemical specie, one may obtain three dimensional crosslinked networks of varying complexity and permeability. The resulting three dimensional networks may be slightly or highly
swellable in a solvent, but the networks remain insoluble. Free molecules of the chemical specie or another compound (that is, molecules that are not covalently bound to the coupling compound) may be incorporated into the three-dimensional network as desired.
The polymeric coupling compound contains an average of at least two latent reactive groups per molecule. Preferably, the average number of such groups per 100 Angstroms extended chain length ranges from 0.05 to 12 and preferably from 0.2 to 2. The coupling compound desirably is formed or derived from a synthetic polymer, although coupling compounds derived from natural polymers also may be employed. DESCRIPTION OF THE PREFERRED EMBODIMENTS
The coupling compounds employed in the present invention are polymeric in nature; that is, they have repeating units and a molecular weight distribution. Most preferably, the coupling compounds are derived from or formed as synthetic polymers. The polymers of the invention include oligomers, homopolymers and copolymers resulting from addition or condensation polymerization, and natural polymers including nucleic acids, oligosaccharides, linear polysaccharides such as amylose, dextran, chitosan, heparin and hyaluronic acid, and branched polysaccharides such as amylopectin, glycogen and hemi-celluloses. The polymers may include several distinct polymer types, as may be prepared by terminal or side chain grafting. The polymers of the invention may include cellulose-based products such as hydroxyethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, nitrocellulose, cellulose acetate and cellulose butyrate, acrylics such as those polymerized from hydroxyethyl acrylate, hydroxyethyl methacrylate, glyceryl acrylate, glyceryl methacrylate, acrylic acid, methacrylic acid, acrylamide and methacrylamide, vinyls such as polyvinyl pyrrolidone and polyvinyl alcohol, nylons such as polycaprolactam, polylauryl lactam, polyhexamethylene adipamide and polyhexamethylene dodecanediamide, polyurethanes and polylactic acids. Of particular importance are the vinyl polymers such as polyvinyl pyrrolidone and
polyacrylamide and the polyethers such as polyethylene glycol. For brevity, the invention is described below primarily with respect to the use of single coupling compounds that are homopoly functional (that is, that bear two or more identical latent reactive groups (and such is preferred)). However, one may employ a mixture of polymeric coupling compounds, if desired, and the coupling compounds themselves may be heteropolyfunctional (that is, they may contain two or more different latent reactive groups) and they may have different properties which they confer upon the matrix.
The polymeric coupling compounds employed in the invention desirably are soluble or at least dispersible in a solvent (to form, for example, a colloidal suspension), and preferably are soluble in water to at least the extent of 1 gram/1 at 23 °C. Moreover, the polymers of the invention desirably have extended chain lengths of at least about 45 Angstroms, and preferably at least about 1000 Angstroms.
"Extended Chain Length", as used herein, refers to theoretical straight line lengths measured along the backbone of a polymeric coupling compound, assuming that the polymer chain is stretched out to its maximum length consistent with observing proper bond angles between adjacent atoms. For example, polyethylene, -(CH.rCH^-, exhibits an "extended" chain length between alternate carbon atoms of about 2.5 A (observing a bond angle of 109.5°), although the sum of the (carbon-carbon) bond distances along the molecule between alternate
carbon atoms is about 3.06 A.
Latent reactive groups, broadly defined, are groups which respond to specific applied external stimuli to undergo active specie generation with resultant covalent bonding to an adjacent chemical structure, e.g., an adjacent same or different molecule. Latent reactive groups are those groups of atoms in a molecule which retain their covalent bonds unchanged under conditions of storage but which, upon activation by an external energy source, form covalent bonds with other molecules. The latent reactive groups generate active species such as free radicals and particularly nitrenes, carbenes, and excited states of ketones upon absorption of external electric, electromagnetic or kinetic (thermal) energy. Latent reactive groups may be chosen to be responsive to various portions of the electromagnetic spectrum, and latent reactive groups that are responsive to e.g., ultraviolet and visible portions of the spectrum are preferred and are referred to herein occasionally as "photochemical" groups. Latent reactive groups as described are generally well known.
The azides constitute a preferred class of latent reactive groups and include arylazides ( N3) such as phenyl azide and particularly 4-fluoro-3-nitrophenyl azide, acyl azides
(-C-N3) such as benzoyl azide and p-methylbenzoyl azide, azido formates (-0-C-
N3) such as ethyl azidoformate, phenyl azidoformate, sulfonyl azides (-S-N3) such as benzenesulfonyl azide, and phosphoryl azides (RO)2P-N3 such as diphenyl phosphoryl azide and diethyl phosphoryl azide. Diazo compounds constitute another class of latent reactive groups and include diazoalkanes (-CHN2) such as diazomethane and diphenyldiazomethane, diazoketones (-C-CHN^ such as diazoacetophenone and l-trifluoromethyl-l-diazo-2-pentanone, diazoacetates (-0-C- CHN^ such as t-butyl diazoacetate and phenyl diasoacetate, and beta-keto-alpha- diazoacetates (-C-C-C-0-) such as t-butyl alpha diazoacetoacetate. Other latent
reactive groups include the aliphatic azo compounds such as azobiscyanovaleric acid, the diasirines ( C ) such as 3-trifluoromethyl-3-phenyldiazirine, and the ketenes (-CH=C=O) such as ketene and diphenylketene. Photoactivatable aryl ketones such as bensophenone and acetophenone are of particular importance inasmuch as these groups are subject to multiple reactivation in water and hence
provide increased coupling efficiency. Peroxy compounds are contemplated as another class of latent reactive groups and include dialkyl peroxides such as di-t- butyl peroxide and dicyclohexyl peroxide and diacyl peroxides such as dibenzoyl peroxide and diacetyl peroxide and peroxyesters such as ethyl peroxybenzoate.
Upon activation of the latent reactive groups, the coupling compounds are covalent'y bound to coupling compound molecules and to chemical species (and, in the preferred embodiment, to the surfaces to which the chemical species are to be co-immobilized), by covalent bonds through residues of the latent reactive groups. Exemplary latent reactive groups, and their residues upon activation, are as follows: Latent Reactive Group Residue Functionality aryl asides amine R-NH-R' acyl asides amide R-C-NH-R' azidoformates carbamate R-O-C-NH-R' sulfonyl asides sulfonamide R-S-NH-R' phosphoryl asides phosphoramide (RO^-NH-R' diasoalkanes new C-C bond diazoketones new CC bond & ketone diasoacetates new C-C bond & ester beta-keto-alpha-diazoacetates new CC bond & B-ketoester aliphatic azo new C-C bond diazirines new C-C bond ketenes new C-C bond photoactivated ketones new C-C bond & alcohol dialkyl peroxides ethers diacyl peroxides esters & new CC bonds peroxyesters ethers, esters, and new C-C bonds The coupling compounds of the invention desirably have an average of at least two and preferably three or more latent reactive groups per molecule. Three- dimensional molecular networks may be formed through the use of polymeric coupling compound molecules each having two or more latent reactive groups, and in general the density of covalent bonds resulting from activation of the reactive groups and hence the "tightness" of the three-dimensional molecular network that is formed will be increased by decreasing the distance between latent reactive groups that are employed in the coupler compound.
Depending upon the method of fabrication of the polymeric coupling compound, that compound may contain varying numbers of latent reactive groups. A bifunctional polymeric coupling compound may have one latent reactive group at each of its two ends. For example, 4-bromomethylbenzophenone (derived from the free radical bromination of 4-methylbensophenone) may be reacted with polyethylene glycol to form a bifunctional coupling compound having -(CH2-CH2- 0)- repeating units and terminating in benzophenone latent reactive groups. Polymeric coupling compounds used in the invention may have latent reactive groups incorporated at random positions along the polymer backbone. It
may in some instances be desirable to provide polymers with more predictable sites for attachment of latent reactive groups, as described further below. Polymeric coupling compounds desirably, but not necessarily, have latent reactive groups at their ends or at random locations along their backbones (spaced from their ends) or both. By "backbone" as used herein in connection with polymer molecules, reference is made to the chain of atoms that is characteristic of the polymer and that results from the polymerization reaction. For example, polyethylene glycol polymers are characterized by a "backbone" of repeating -(-
CH2-CH2-O-)- groups, whereas polyacrylamide and polyvinyl pyrrolidone have backbones characterized by carbon-carbon bonds, alternating carbon atoms in the backbone having pendent amide or pyrrolidone groups, respectively.
A polymer that includes at least one latent reactive group along its backbone spaced from its ends can be prepared by copolymerizing the basic monomer or monomers for the polymer with a monomer to which can be readily attached a latent reactive group such as a photoreactive group. For example, a photoreactive polyacrylamide polymer can be obtained by copolymerizing acrylamide with a small quantity of N-(3-aminopropyl)methacrylamide to provide random amine-functional groups along the polymer backbone, and then reacting the polymer with an amine-reactive photoreactive reagent such as benzoylbenzoylchloride. Coupling compounds may be derived from naturally
occurring polymers such as hyaluronic acid by known methods such as those taught in U.S. Patent 5,002,582, the teachings of which are incorporated herein by reference. The polymeric coupling compounds employed in the present invention desirably carry a sufficient number of latent reactive groups so that the average number of latent reactive groups per 100 Angstrom extended chain length ranges from 0.05 to 12 and preferably from 0.2 to 2. The chemical species which can be co-immobilized together with the coupling compound in a three dimensional network according to the invention may be chosen from a wide variety of suitable substances. The chemical species used herein preferably are free of latent reactive groups of the type carried by the coupling compounds, that is, latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compounds during the activation step. If desired, two or more chemical species may be employed, each lending to the matrix its particular properties. For example, it may be desired to immobilize at the same time an anticoagulant such as heparin, a thrombolytic agent such as streptokinase and, if desired, a protease inhibitor.
Some chemical species and the desired properties that these species exhibit when co-immobilized upon a surface are exemplified in the following non-limiting list:
CHEMICAL SPECIES FUNCTIONAL ACTIVITY
Synthetic Polymers Sulfonic acid-substituted Lubricity, negatively charged surface polyacrylamide Polyacrylamide Lubricity, protein repulsion Polyethylene glycol Lubricity, cell and protein repulsion Polyethyleneimine Positively charged surface Polylactic acid Negatively charged surface Polyvinyl alcohol Lubricity Polyvinyl pyrrolidone Lubricity Quaternary amine-substituted Lubricity, positively charged surface polyacrylamide Silicones Lubricity Conductive polymers (e.g., Electric conductivity polyvinylpyridine polyacetylene, polypyrrole
Carbohydrates
Alginic acid Lubricity, hydrophilicity
Cellulose Lubricity, hydrophilicity, biodegradable glucose source
Figure imgf000015_0001
streptokinase, plasmin)
Lipids
Fatty acids Hydrophobicity, biocompatibility
Mono-,di- and triglycerides Hydrophobicity, lubricity, biodegradable fatty acid source
Phospholipids Hydrophobicity, lubricity, biodegradable fatty acid source
Prostaglandins/leukotrienes Nonthrombogenic surface/immobilized messengers
Nucleic Acids
DNA Substrate for nucleases/affinity binding
RNA Substrate for nucleases/affinity binding
Nucleosides, nucleotides Source of purines, pyrimidines, enzyme cofactors
Drugs/vitamins/cofactors Enzyme cofactors Immobilized enzymes Heme compounds Globin binding/surface oxygenation Drugs Drug activity
Non-polymeric Materials
Dyes (e.g., azo dyestuffs) Coloring agents Fluorescent compounds Fluorescence
(e.g., fluorescein)
The product that is formed via activation of the latent reactive groups carried by the coupling compound is an insoluble, three dimensional crosslinked matrix that is desirably in solid or at least semi-solid (e.g., gel) form and that exhibits the properties of the chemical specie(s) incorporated in it, or properties of the coupling compound(s), or both. The coupling compound may be a polymer that itself provides the matrix with valuable properties; for example, use of a photo- derivatized polyvinylpyrrolidone may confer slipperiness and water wettability to the matrix. Both the coupling compound and the chemical specie may provide the matrix with desired properties. For example, a matrix formed from photopolyacrylamide as the polymeric coupling compound and heparin as the chemical specie may exhibit a reduction in protein absoφtion characteristic of the polyacrylamide and the antithrombogenic activity characteristic of heparin.
The matrices may be in the form of fibers, beads or other particles (for use, for example, in chromatographic columns), or in the form of free-flowing or non-flowing gels. However, the matrices preferably are in the form of films which may be continuous or discontinuous and which may have thicknesses ranging from a few nanometers up to a millimeter or more. A film may be self supporting, as when in sheet or tubing form; it may be in the form of a coating formed on and supported by a surface and in its most preferred form covalently bonded to the surface. The crosslink density of the three-dimensional polymeric network that is
formed can be varied as desired by judicious choice of the type and the amount of the coupling compound. For example, the use of polymeric coupling compounds that contain relatively few latent reactive groups will result in fewer covalent
bonds being formed per unit length measured along the extended backbone of the polymer or per unit of molecular weight of the polymer, and the resulting three- dimensional network will be more open; that is, it will have a larger effective pore size. The use of polymeric coupling compounds having a greater number of latent reactive groups, or, for that matter, having latent reactive groups concentrated along a certain portion of the molecule, will provide a more tightly crosslinked, dense three-dimensional matrix.
The tightness of the three-dimensional network that is formed will depend upon the density of covalent bonds formed from the latent reactive groups carried by the coupling compound and this, in turn, depends upon the number of latent reactive groups per molecule of the coupling compound and the relative amounts of coupling compound and chemical specie that are employed. Of course, the ability of the polymeric coupling compound to become extended in solution (in contrast to assuming a tightly coiled configuration) also contributes to the loftiness or openness of the three dimensional network, and polymeric coupling compounds that are soluble to the extent of at least about 1 g/1 in water are preferred.
The three-dimensional network that is formed in accordance with the method of the invention not only has utility in providing the resulting film with characteristics of the co-immobilized chemical specie, but also has utility in that it can be used to capture free chemical species (chemical species not covalently bound to a coupling compound molecule) so that the matrix, when in contact with a suitable liquid medium such as an aqueous solution, may gradually release the
free chemical specie into the medium. The quantity of chemical specie that is thus released by the three-dimensional polymer network and the rate of release may depend upon a number of factors, including the loftiness or openness of the three- dimensional network, the amount of the free chemical specie that is employed, and the degree of affinity or repulsion between the three-dimensional network and the chemical specie.
In a preferred embodiment, the polymeric coupling compound and the chemical specie exhibit an affinity permitting them in solution to assume a preferred orientation with respect to each other prior to activation of the latent
reactive groups, thereby facilitating covalent bonding therebetween when the latent reactive groups are activated. The affinity of the coupling compound and the chemical specie may involve the hydrophobic or hydrophilic characteristics of these compounds, e.g., in which hydrophobic portions of these compounds preferentially orient next to each other. The affinity between the coupling compound and the chemical specie may involve ionic attraction between portions of the molecules. For example, the polymeric coupling compound may be polyionic and the chemical specie also may be ionic, the coupling compound having a net charge opposite the net charge of the chemical specie. The coupling compound may be a vinyl copolymer containing aminopropyl pendent groups resulting from the use of an aminopropylmethacrylate monomer, the coupling compound thus having a net positive charge. The chemical specie may be a dextran sulfate having a net negative charge. In this embodiment, prior to the step of activating the latent reactive groups, the coupling compound and the chemical specie are brought into association permitting ionic attraction between them to pre- orient the chemical specie and the polymeric coupling compound with respect to each other before they are covalently bonded. Desirably, the polyionic coupling
compound and the ionic chemical specie are provided in solution together to facilitate ionic attraction between them.
Free chemical species may be positioned or entrapped within the three- dimensional network that is formed by being present during formation of the network or by being added after the network has been formed. By employing a large amount of the chemical specie in comparison to the coupling compound, one may ensure that at least some of the chemical specie will not become covalently bound to the coupler, and the resulting free chemical specie may thus become physically entrapped within the network, and some may be slowly released.
If substantially all of the chemical specie becomes involved via covalent bonding within the three-dimensional network, additional chemical specie may be incoφorated in the network by replacing the solvent that is present in the network with a solvent solution containing the chemical species. For example, solvent may be removed from a film that is initially formed, and the dried film may then be contacted with a solution of an additional quantity of the same or a different chemical species, causing molecules of the chemical species to enter the network and to become trapped therein upon removal of the solvent in a subsequent drying procedure. The resulting films, when placed in contact with a liquid medium such as blood or an open wound containing serous fluid, will release molecules of the free chemical species into the blood or serous fluid, the amount and rapidity of the release of the chemical agent depending upon how readily the chemical species can migrate from the coating into the blood or serous fluid, and, of course, upon the concentration gradients of the chemical species that are established. The remaining film, however, will yet retain molecules of the chemical species covalently bonded to it such that it will continue to itself exhibit characteristics of the chemical species. For example, heparin may be co-immobilized with a photoderivatised polyacrylamide coupling compound upon a surface, the process making use of a large amount of heparin so that some of the heparin is not covalently bonded to the polyacrylamide. The resulting film, when brought into contact with blood, releases heparin into the blood at a decreasing rate over a period of time. Once all of the available free heparin has escaped from the surface of the film into the blood, the heparin molecules that are covalently bound to the surface will continue to provide the surface with the antithrombogenic characteristics of heparin, If desired, the three-dimensional network that is formed may be chosen to be subject to destruction in use. For example, the network may include ester linkages that are cleavable by the esterases in blood issuing from a wound. For example, a protective coating may be made from a vinyl polymer coupling compound containing aminoethylmethacrylate mere units to which latent reactive groups are coupled and a biologically active chemical species such as heparin.
The coating may slowly degrade when in contact with blood due to hydrolysis of the ester bonds by esterases in the blood. In this manner, chemical species containing heparin and having the antithrombogenic properties of heparin may be slowly released. If desired, free molecules of other chemical species (that is, molecules not covalentiy bound to the coupling compound) can be incoφorated in the three- dimensional matrix. For example, as taught in greater detail below, photopolyacrylamide and heparin may be co-immobilized on a surface, and an
antibiotic such as cephalosporin or vancomycin may be incoφorated in the matrix.
Upon contact with blood, the antibiotic is released gradually by being leached from the surface, leaving behind a heparinized surface. Different free molecules of various chemical species may be incoφorated in a single matrix in this manner. For example, several antibiotics may be employed which exhibit activity against different microorganisms, or which provide more effective control over a single microorganism. If it is desired to form the film upon a surface to which the film is covalentiy bonded as it is formed, then the latent reactive groups that are employed are preferably attracted to the surface to be coated so that the latent reactive groups will readily come into covalent bonding proximity with the surface. Photochemical groups such as the aryl asides and the aromatic ketones commonly are relatively hydrophobic, as are many of the solid surfaces (e.g., polystyrene, polysulfone arid polyolefin) that may be coated in accordance with the invention. "Hydrophilic" and "hydrophobic" are used herein to describe compositions broadly, as water loving and water hating, respectively, in line with the following observations: Hydrophilic compounds are usually relatively polar and often are ionizable. Such compounds usually bind water molecules strongly. Hydrophobic compounds are usually relatively non-polar and non-ionizing. Hydrophobic surfaces will generally cause water molecules to structure in an ice¬ like conformation at or near the surface. "Hydrophobic" and "hydrophilic" are relative terms, of course, and are used herein in the sense that various compositions, liquids and surfaces may be hydrophobic or hydrophilic relative to one another. A discourse on the subject is found in Hoffman, Letter to the Editor: A general classification scheme for "hydrophilic" and "hydrophobic" biomaterial surfaces. J. Biol. Mat. Res. 20,pp. ix-xi (1986).
Crosslinked, three-dimensional matrix films of co-immobilized coupling compound and chemical species can be produced by combining the polymeric coupling compound and chemical species precursors in solution and then physically forming the solution into a sheet or film configuration before activating the latent reactive groups. For example, an aqueous solution of the precursors may be floated upon the surface of a non-miscible liquid such as a perfluorocarbon liquid. After activating the latent reactive groups of the polymeric coupling compound, the film, which may at this point be self-supporting, may be removed from the liquid surface. It is contemplated that this process may be performed on a continuous basis if desired, the precursor solution being sheeted onto a bath of the non-miscible liquid at one end of the bath, and the continuous self-supporting film being removed from the other end of the bath. The surface upon which the film is physically formed may be a solid surface such as polytetrafluoroethylene to which the latent reactive groups, when activated, do not readily bond and from which the film may be removed.
The method of the invention finds particular utility, however, in the formation of a film upon a surface, desirably a solid surface, to which the film becomes covalently bonded by latent reactive groups of the coupling compound. In this embodiment, the surface itself becomes chemically involved in the formation of the three-dimensional matrix. Such surfaces preferably have abstractable hydrogen atoms and participate readily in the formation of covalent bonds upon activation of the latent reactive groups.
In the preferred process of the invention, the coupling compound and the
selected chemical specie (several coupling compounds or chemical species or both may be used) are applied to a surface, and the latent reactive groups of the coupling compounds are simultaneously reacted to form covalent bonds between the chemical specie and the coupling compound, between the coupling compound and the surface, and between different molecules of the coupling compound, to form a three dimensional molecular network. If desired, the coupling compound and the chemical specie may be combined and partially pre-reacted before they are applied to the surface.
To facilitate the co-immobilization process, the polymeric coupling compound and the chemical specie are applied to a surface from a solvent medium, preferably from solution and most preferably from aqueous solution.
Preferably, the coupling compound and the chemical specie are combined in solution and applied as a wet film to the surface, following which the latent reactive groups are activated, by light, in the case of photoreactive groups. Solvent may be partially or totally removed from the wet film before activation of the latent reactive groups. Alternatively, the latent reactive groups may be reacted in the presence of the solvent. The coupling compound and the chemical specie may be applied to the surface as separate, wet films which blend or interdiffuse together to bring the coupling compound and the chemical specie into covalent bonding proximity, and it is contemplated that the first wet film may be at least partially dried before application of the second film.
Defined broadly, the "surface" upon which may be formed a film according to the invention is defined by the interface between distinct phases of compositions, the solid surface of a tangible object such as a sheet of material being perhaps the most commonly thought of surface and being defined by a gas- solid interface. Surfaces may be defined by the interface between liquid and solid compositions as exemplified by the solid surface of solid particles in suspension, by the interface between immiscible liquids as exemplified by emulsions, and by gas-liquid interfaces as exemplified by the surface of a liquid bath.
A solid surface as referred to herein is a tangible surface defined by the interface between solid phase materials (including soft gels) and gas or liquid phases. Specific examples include the surfaces of medical devices such as blood bags, catheters, bone and tissue prostheses, and living bone and tissue surfaces. Other solid surfaces are exemplified as the surfaces of membranes, fibers such as hollow fibers employed in chemical reactors and fibers employed in structural composites, and chromatographic media particles and the like.
The invention may be more easily understood by reference to the following illustrative, non-limiting examples:
EXAMPLE 1: Preparation of Bis(benzoylbenzyl)
Polyethyleneglycol Ether (BBE-PEG(3350)-BBE) To 100 g of polyethylene glycol 3350 (PEG(3350)) in a 1 liter round bottom flask was added 400 ml of toluene. The toluene was evaporated off to remove moisture. The PEG was then dissolved in tetrahydrofuran (250 ml) by stirring at reflux temperatures under an argon atmosphere, and the solution was allowed to cool. To the solution was added NaH (2.3 g) and the solution was stirred for an hour, after which 20.5 g of bromomethylbenzophenone was added.
The cloudy mixture was stirred overnight. Ammonium chloride (10.2 g) and water (4 ml) were added and the mixture was stirred for 30 minutes. The solvent was evaporated off, and 150 ml of toluene was added and the cloudy solution was filtered to obtain a clear filtrate. The clear solution was then slowly added to 300 ml of ice cold diethyl ether to precipitate the polymer which was then collected by filtration, washed "with ethyl ether and dried.
EXAMPLE 2: Preparation of Photoderivatized Polyacrylamide (Photo PAA)
Acrylamide (10.24 g) was dissolved in 200 ml of deionized water. To the solution was added 0.279 mg of N-(3-aminopropyl)methacrylamide, 0.33 g of ammonium persulfate and 0.155 g of N^NSN'-tetramethylethylenediamine. The solution was evacuated in a filter flask with a water aspirator for 10 minutes. The tubing was clamped and the solution left under vacuum for one hour. The resulting polymer solution was dialyzed against deionized water. To 150 ml of polymer solution in a PTFE bottle containing 3.0 g of polymer was added 0.504 ml of triethylamine. To this solution was added 30 ml of 28.4 mg/ml 4- benzoylbensoylchloride in CHC13. The bottle was capped tightly and shaken for one hour. The bottle was then centrifuged for 10 minutes to separate the phases after which the aqueous layer was removed, dialyzed and lyophilized. EXAMPLE 3: Co-immobilization of Polyvinylpyrrolidone 1.0 gm of polyvinylpyrrolidone (PVP) having a number average molecular weight of about 360,000 was dissolved in 25ml of water. 350 mg of BBE- PEG(3350)-BBE prepared as in Example 1 were dissolved in 25 ml of water. The solutions were mixed and lyophilized. 100 mg samples were illuminated with ultraviolet light for 10 seconds and for 10 minutes, respectively, to achieve limited pre-reaction of the photoreactive groups carried by the photopolyethylene glycol. The dry mixtures were redissolved in water and diluted to give a solution that was 4.5 mg/ml in 30% isopropanol. 65 ul of these solutions were sprayed onto one side of a 1" x 1" piece of polymethylmethacrylate (PMMA), and the coating was irradiated with ultraviolet light for 3 minutes. Both samples were readily wettable with water. After washing, the wet films were slippery when rubbed with the fingers (a characteristic of PVP but not of PMMA or photo PEG), indicating that the PVP had been bound to the surface. EXAMPLE 4: Heparin Co-immobilized onto Regenerated Cellulose and Polysulfone Hollow Fiber Dialysis Membranes.
Heparin was dissolved at 3 mg/ml in an aqueous solution of photo PAA prepared as in Example 2 at 3 mg/ml for subsequent co-immobilization on membrane surfaces. Another aqueous solution was prepared by dissolving heparin at 6 mg/ml in photo PAA at 3 mg/ml. A photoreactive derivative of heparin (photoheparin) was prepared by reacting heparin with benzoyl-benzoyl-epsilon- aminocaproyl-N-oxysuccinimide in dimethylsulfoxide/carbonate buffer, pH 9.0. The solvent was evaporated and the photoheparin was dialyzed vs. water, and lyophilized, and then dissolved in water at 3 mg/ml. Heparin was also dissolved in water at 3 mg/ml for subsequent absoφtion onto membrane surfaces. Each solution was applied to specimens of regenerated cellulose membranes by soaking overnight at 37°C. The membranes were then dried and UV illuminated in a N2 atmosphere for 2 minutes. The membranes were then washed four times for three minutes each in an ultrasonic bath of 0.5% Tween 20 in phosphate buffered saline
(PBS) followed by the same washing procedure in deionized water. The membranes were further washed for 24 hours in 0.5% Tween 20 followed by a 24-hour wash in 1% bovine serum albumin (BSA). Heparin activity was then measured by a Factor Xa inhibition assay. The results are given below.
Regenerated Cellulose
Immobilization Condition He arin Activi m /cm2
Figure imgf000027_0001
In a similar experiment, heparin at several concentrations was coimmobilized with photo-PAA as described above onto polysulfone hollow fiber membranes. After washing, the heparin activity was measured, yielding the following results:
Heparin Concentration, mg/ml Heparin Activity (mU/cm2) 6.0 8.4+ 2.5
2.5 8.4± 1.9
1.0 7.2± 1.3
0.6 4.6± 1.4 EXAMPLE 5: Collagen Co-immobilized onto PTFE Membranes for Cell
Culture.
Photo PAA was prepared as follows: To 2 grams of N-(3-aminopropyl)methacrylamide (APMA) in 80 ml of dry dimethylsulfoxide was added 4.96 gm of 4-bensoylbenzoyl-epsilon- aminocaproyl-N-oxysuccinimide and 2.26 ml of N,N,N'N'- tetramethylethylenediamine. The solution was stirred for four hours, after which 20 gm of acrylamide in 286 ml of DMSO and 300 mg of azobis(isobutyronitrile) in 100 ml of DMSO were added. The solution was bubbled with helium for 5 minutes, after which the space above the solution was filled with argon. Polymerization was allowed to occur at 55°C for 24 hours. The polymer was then precipitated in ethanol, redissolved in 250 ml of deionized water, and dialyzed vs. water. Insoluble material was removed by filtration, and the clear solution was lyophilized.
Polytetrafluoroethylene (PTFE) membranes were first prewetted with methanol and then were soaked for 4 hours in an aqueous solution (5 mg/ml) of the photo PAA prepared above. The coatings then were illuminated with UV light for 3 minutes and washed in PBS. Native bovine skin collagen (containing types I and III) at 1.25 mg/ml was dialyzed vs. 3 mM HC1, and the photo PAA prepared as above was dissolved in the collagen solution at 5 mg/ml. Porous PTFE membranes that previously had been coated with photo PAA and irradiated were then soaked in the solution for 4 hours at 4°C. The membranes were illuminated with UV light for 3 minutes, after which they were washed extensively with PBS and air dried.
The collagen-coated membranes thus produced were tested in cell culture studies using both PA-I (human, ovarian) and NRK (rat, kidney) cell lines and demonstrated good cell attachment and growth. EXAMPLE 6: Co-immobilization of Streptokinase
Polyethylene tubing was filled with a solution containing 2.5 mg/ml photo PAA prepared as in Example 5 and 2.5 mg/ml streptokinase, after which the tubing was UV illuminated for 8 minutes. After rinsing the tubing by circulating
buffer through it for 24 hours, streptokinase activity was detected in the tubing by adding plasminogen (0.5 units/ml) and D-val-leu-lys-p-nitroanilide and measuring at 405 nm the color generated by release of p-nitroaniline.
EXAMPLE 7: Co-immobilization of Photopolyacrylamide and Heparin to
Polyvinylchloride Tubing Photopolyacrylamide prepared as in Example 3 was dissolved in water at
25 mg/ml. Sodium heparin was dissolved in water at 50 mg/ml. 20 ml of the photo PAA solution prepared as in Example 2 and 5 ml of the heparin solution were mixed to give 25 ml of co-immobilization solution containing 30 mg/ml of total solids. External surfaces of polyvinylchloride tubing were precleaned with an alcohol wipe followed by argon plasma treatment and then were dipped in the co- immobilization solution. Excess solution was drained away, the coating was air dried, and a second, identical coating application was performed. The tubing was
exposed to UV light to cure the hydrogel-heparin matrix. Surface treatment of the polyvinylchloride by this two-coat process resulted in heparin activity levels of 3500 mU/cm2 as measured by a thrombin inhibition assay. Long term exposure of these coated materials to albumin-containing phosphate-buffered saline (intended to simulate blood contact) gave significant release of soluble heparin and also resulted in immobilized heparin activities of approximately 10 mU/cm2. EXAMPLE 8: Co-immobilization of Photo PAA and Heparin to a Surface with Subsequent Loading and Release of Antimicrobial Agents. Photo PAA, as prepared in Example 2, and heparin are co-immobilized upon a surface as described in Example 7. After rinsing away the unbound heparin with water and subsequently drying the coating, the immobilized polyacrylamide-heparin matrix is placed overnight in an aqueous solution containing 100 mg/ml of vancomycin. The tubing is removed and air-dried. Upon subsequent blood contact with the tubing, the antibiotic is released from the photo PAA-heparin hydrogel at a gradually decreasing rate. Complete release of the matrix-adsorbed drug leaves a biocompatible heparinized, hydrogel surface. EXAMPLE 9: Preparation of Co-immobilized Photo PAA/Hyaluronic Acid
Film To 10 ml of a 10 mg/ml solution of hyaluronic acid in water was added 200 mg of the photo PAA prepared in Example 5. The viscous solution was spread onto a polytetrafluoroethylene (PTFE) textured surface, was allowed to dry, and was illuminated with ultraviolet light. The resulting film was removed from the PTFE surface as an intact film, the pattern of the textured PTFE being evident on the lower surface of the film. When wet with water, the film swelled but did not dissolve. A solution of hyaluronic acid alone was also spread on an identical film, dried and illuminated. The resulting film readily redissolved in water. EXAMPLE 10: Polyethylene Glycol Co-immobilization onto Polycarbonate
Membranes. The mono benzoylbensyl ether of polyethylene glycol (BBE-PEG-OH) was synthesized using polyethylene glycol (HO-PEG-OH) by the following procedure: To polyethylene glycol (20 g, mol. wt. 8000) dissolved in 100 ml of dry tetrahydrofuran (THF) was added 60 mg of NaH followed by stirring under a
positive N2 pressure for 2 hours. 4-Bromomethylbenzophenone (344 mg) was added and the solution was stirred overnight under a positive N2 pressure. The reaction was quenched by adding 267 mg of NH4CI in 2 ml of water. The THF was evaporated off, then the polymer was dissolved in 100 ml of saturated NaCl solution. The solution was extracted twice with 100 ml of CHC13. The
chloroform solution was dried over Na2SO4. The solvent was evaporated and the resulting BBE-PEG-OH polymer was dissolved in and precipitated from toluene/ethyl ether.
A mixture of equal weights of BBE-PEG-OH, HO-PEG-OH and the BBE- PEG-BBE of Example 1 was dissolved at 0.5 mg/ml in a 50% isopropanol solution in water. Commercially available porous polycarbonate membranes were soaked in the resulting solution for 10 minutes and were dried in a cold air stream for 3 minutes. The membranes were exposed to UV radiation for 10 seconds, and then were washed in water for 15 minutes and air dried. The wettability of the membranes, as measured by the ease with which an aqueous solution passes through them, was tested by measuring the time required to pass 500 ml of water through 47 mm diameter discs under a pressure drop across the discs of 625 mm Hg. 14 Minutes were required for the discs prepared above, whereas 17 minutes were required for identical polycarbonate discs that were treated instead by soaking in a polyvinyl pyrrolidone solution. For comparison, water under this pressure differential will not pass through an uncoated polycarbonate disc. EXAMPLE 11 : Synthesis of Polyionic Polymeric Coupling Compound
To 85 mg of N-(3-aminopropyl)methacrylamide in 5 ml of dry dimethylsulfoxide was added 102 mg of benzoylbenzoyl-epsilon-aminocaproyl-N- oxysuccinimide and 40 ul of NjNjN'N'-tetramethylethylenediamine. The solution was stirred overnight, after which 1.0 gm of N- acryloyltris(hydroxymethyl)aminomethane in 5 ml of DMSO and 50 mg of azobis(isobutyronitrile) in 5 ml of DMSO were added. The solution was bubbled with nitrogen for 5 minutes, sealed and stored at 55°C overnight. The resulting polymer was precipitated in ethanol, redissolved in 10 ml of deionized water, dialyzed vs. water and lyophilized.
EXAMPLE 12: Coimmobilization of Dextran Sulfate onto Polystyrene Beads for Purifying Clotting Factors from Blood. The ionic polymer prepared in Example 11 and the photo PAA prepared as in Example 5 were each dissolved in deionized water at 5 mg/ml. To each solution dextran sulfate (average molecular weight of 500,000) was added at 10 mg/ml. These solutions were incubated with polystyrene beads (297-1000 urn diameter) for 24 hours at room temperature with mixing. The beads were then filtered to remove coating solutions and air dried. The beads were then spread into thin layers on aluminum foil, illuminated with UV light for 1.5 minutes, shaken, and illuminated for an additional 1.5 minutes. The beads were then washed with deionized water and tested for ability to bind Azure A (which turns from blue to puφle upon binding to a sulfated surface). By visual observation, both preparations of coated beads were significantly colored but the beads coated with dextran sulfate coimmobilized with the polyionic polymeric coupling compound were significantly more puφle than the beads coated with dextran sulfate coimmobilized with the photo PAA, which is indicative of a higher concentration of dextran sulfate coimmobilized with the ionic coupling compound. While a preferred embodiment of the present invention has been described, it should be understood that various changes, adaptations and modifications may be made therein without departing from the spirit of the invention and the scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. Method for immobilizing a chemical specie in a matrix that includes the chemical specie and a separate coupling compound to provide the matrix with properties of the chemical specie, the coupling Compound or both, comprising a. bringing together in covalent bonding proximity a desired chemical specie and a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to another coupling compound molecule or to the chemical specie; and b. simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other.
2. The method of claim 1 wherein the chemical specie is free of latent reactive groups that are activated during activation of the latent reactive groups of the coupling compound.
3. The method of claim 2 including the step of providing a mixture of the chemical specie and the polymeric coupling compound in a solvent solution, and forming a film from the solution before activation of the latent reactive groups.
4. The method of claim 3 including the step of spreading the. solution upon a surface to form said film on the surface.
5. The method of claim 4 wherein said surface is the surface of a liquid.
6. The method of claim 4 wherein said surface is a solid surface.
7. The method of claim 6 wherein, upon activation of said latent
reactive groups, covalent bonds are simultaneously formed between the coupling compound and the surface.
8. The method of claim 2 wherein the coupling compound is a
bifunctional polymeric coupling compound having a latent reactive group at each end.
9. The method of claim 2 wherein the coupling compound has at least one latent reactive group along its length spaced from its ends.
10. The method of claim 2 wherein said coupling compound is a photoderivatized vinyl polymer.
11. The method of claim 10 wherein said coupling compound is a photoderivatized polyacrylamide or a photoderivatized polyvinylpyrrolidone.
12. The method of claim 2 wherein said coupling compound is a photoderivatised polyether. —
13. The method of claim 12 wherein said coupling compound is a photoderivatised polyethylene glycol.
14. The method of claim 2 wherein said polymeric coupling compound and chemical specie exhibit affinity permitting them in solution to assume a preferred orientation with respect to each other prior to activation of the latent reactive groups to facilitate covalent bonding therebetween when the latent reactive groups are activated, the method comprising the step of bringing the coupling compound and the chemical specie into association permitting then to assume said
preferred orientation prior to activation of the latent reactive groups of the coupling compound.
15. The method of claim 14 wherein the coupling compound is polyionic and the chemical specie is ionic, the coupling compound having a net charge opposite the net charge of the chemical specie, the method including the step of bringing the coupling compound and the chemical specie into association permitting ionic attraction therebetween prior to activation of the latent reactive groups of the coupling compound.
16. Method for forming a matrix having a first chemical specie immobilized therein and including free molecules of a second chemical specie whereby the second chemical specie molecules may be gradually released from the matrix, comprising a. bringing together in covalent bonding proximity a first chemical specie and a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to another coupling compound molecule or to the chemical specie; b. simultaneously activating the latent reactive groups to cause formation via covalent bonding of a three-dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound, and molecules of the coupling compound are covalently bonded to each other, and c. contacting the three dimensional network with a second, different chemical species under conditions favoring incoφoration of the second chemical species in said three dimensional network.
17. The method of claim 16 wherein said first chemical specie is an antithrombic agent and said second chemical species is an antibiotic.
18. Method for covalently immobilizing to a surface a chemical specie comprising a. forming on the surface a coating of the chemical specie together with and in covalent bonding proximity to a polymeric coupling compound having at least two latent reactive groups per molecule, each latent reactive group being capable of covalently bonding to another coupling compound molecule, to the chemical specie or to the surface; and b. simultaneously activating said latent reactive groups to cause formation via covalent bonds of a three dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound and molecules of the coupling compound are covalently bonded to each other and to the surface.
19. The method of claim 18 wherein the chemical specie is free of latent reactive groups that are activated during activation of the latent reactive groups of the coupling compound.
20. The method of claim 19 including the step of providing a mixture of the chemical specie and the polymeric coupling compound in a solvent solution, and forming a coating of the solution on the surface.
21. The method of claim 20 including the step of evaporating solvent from the solution prior to activating said latent reactive groups.
22. The method of claim 20 including the step of activating the latent reactive groups in the presence of the solvent.
23. The method of claim 19 including the steps of providing separate but contiguous and interdiffusing coating layers on the surface, one layer comprising a solution of the chemical specie and the other layer comprising a solution of the coupler.
24. The method of claim 23 wherein the layer comprising the solution of the coupler is positioned nearer the surface than the solution of the chemical specie.
25. The method of claim 19 wherein sufficient excess of the chemical specie is employed in the solution to provide free molecules of the specie which are not covalently coupled to the coupling compound upon reaction of the reactive groups, and wherein at least a portion of said free molecules are carried by and within the three dimensional network.
26. The method of claim 25 including the step of activating the latent reactive groups in the presence of the solvent.
27. The method of claim 20 wherein the coupling compound is polyionic and the chemical specie is ionic, the coupling compound having a net charge opposite the net charge of the chemical specie, the method including the step of bringing the coupling compound and the chemical specie into association permitting ionic attraction therebetween prior to activation of the latent reactive groups of the coupling compound.
28. Method of providing a surface with a coating contaiiiing both
immobilized and free molecules of a desired chemical specie whereby free molecules of the specie may be gradually released from the surface and the immobilized molecules of the specie remain on the surface, comprising forming on the surface a coating of the chemical specie together with and in covalent bonding proximity to a polymeric coupling compound having at least two latent reactive groups each capable of reaction upon activation to form covalent bonds to itself, to the chemical specie or to the surface, said specie being free of latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compound; and simultaneously activating the latent reactive groups of the coupling compound to cause formation via covalent bonds of a three dimensional molecular network in which molecules of the chemical specie are covalently bonded to molecules of the coupling compound and molecules of the coupling compound are covalentiy bonded to each other and to the surface, the method
including the step of employing sufficient excess of the chemical specie to provide free molecules of the specie which are not covalently coupled to the coupling compound upon reaction of the reactive groups, at least a portion of said free molecules being carried by and within the three dimensional network.
29. Method of providing a surface with a coating containing immobilized molecules of a first chemical specie and free molecules of. a second, different chemical specie, whereby the second chemical specie molecules may be gradually released from the surface, comprising forming on the surface a coating of the first chemical specie together with and in covalent bonding proximity to a polymeric coupling compound having at least two latent reactive groups each capable of reaction upon activation to form covalent bonds to itself, to the first chemical specie or to the surface, said first chemical specie being free of latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compound; and simultaneously activating the latent reactive groups of the coupling compound to cause formation via covalent bonds of a three dimensional molecular network in which molecules of the first chemical specie are covalently bonded to molecules of the coupling compound and molecules of the coupling compound are covalently bonded to each other and to the surface, the method including the step of contacting the three dimensional network thus formed with said second chemical species under conditions favoring incorporation of the
second chemical species in said three dimensional network.
30. The method of claim 29 wherein said first chemical specie is an antithrombic agent and said second chemical species is an antibiotic.
31. Method for covalently immobilizing to a surface a chemical specie comprising a. forming on the surface a coating of the chemical specie together with and in covalent bonding proximity to a polymeric coupling compound having an average of at least two latent reactive groups per molecule and wherein the number of latent reactive groups per 100 Angstroms of the extended chain length of the polymer ranges from 0.05 to 12, each latent reactive group being capable upon activation by actinic radiation of covalent bonding to another polymer molecule, to the chemical specie or to the surface, the chemical specie being free of latent reactive groups that are activated upon activation of the latent reactive groups of the coupling compound; and b. simultaneously activating the latent reactive groups of the coupling compound to cause formation via covalent bonds of a three dimensional molecular network of said polymer molecules in which molecules of the chemical specie are covalentiy bonded to molecules of the polymer and molecules of the polymer are covalently bonded to each other and to the surface.
32. The method of claim 1 wherein the latent reactive groups of the coupling compound are groups which respond to specific applied external electromagnetic radiation to generate active species selected from the group consisting of carbenes, nitrenes and excited states of ketones.
33. The method of claim 32 wherein the latent reactive groups are photochemically reactive groups.
PCT/US1993/001248 1992-02-13 1993-02-11 Immobilization of chemical species in crosslinked matrices WO1993016176A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002107683A CA2107683C (en) 1992-02-13 1993-02-11 Immobilization of chemical species in crosslinked matrices
JP51429293A JP3455217B2 (en) 1992-02-13 1993-02-11 Immobilization of chemical species in crosslinked matrix
AT93905897T ATE192487T1 (en) 1992-02-13 1993-02-11 IMMOBILIZATION OF A CHEMICAL SPECIES IN A NETWORKED MATRIX
EP93905897A EP0585436B1 (en) 1992-02-13 1993-02-11 Immobilization of chemical species in crosslinked matrices
DE69328523T DE69328523T2 (en) 1992-02-13 1993-02-11 IMMOBILIZATION OF A CHEMICAL SPECIES IN A NETWORKED MATRIX

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83520692A 1992-02-13 1992-02-13
US07/835,206 1992-02-13

Publications (1)

Publication Number Publication Date
WO1993016176A1 true WO1993016176A1 (en) 1993-08-19

Family

ID=25268915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001248 WO1993016176A1 (en) 1992-02-13 1993-02-11 Immobilization of chemical species in crosslinked matrices

Country Status (9)

Country Link
US (1) US5563056A (en)
EP (1) EP0585436B1 (en)
JP (1) JP3455217B2 (en)
AT (1) ATE192487T1 (en)
AU (2) AU3664693A (en)
CA (1) CA2107683C (en)
DE (1) DE69328523T2 (en)
ES (1) ES2145044T3 (en)
WO (1) WO1993016176A1 (en)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018665A1 (en) * 1994-01-10 1995-07-13 Hemasure, Inc. Device and process for removing leukocytes and viral inactivating agents from blood
WO1996022062A1 (en) * 1995-01-17 1996-07-25 Allergan Iol insertion apparatus and method for using same
US5639376A (en) * 1994-01-10 1997-06-17 Hemasure, Inc. Process for simultaneously removing leukocytes and methylene blue from plasma
WO1997046267A1 (en) * 1996-06-03 1997-12-11 Gore Enterprise Holdings, Inc. Materials and methods for the immobilization of bioactive species onto biodegradable polymers
US5803925A (en) * 1995-01-17 1998-09-08 Allergan IOL insertion apparatus with covalently bonded lubricant
WO1999008717A2 (en) * 1997-08-15 1999-02-25 Surmodics, Inc. Latent reactive polymers with biologically active moieties
US5942277A (en) * 1996-07-10 1999-08-24 Allergan IOL insertion apparatus and method for making and using same
US6083230A (en) * 1997-07-30 2000-07-04 Allergan Method for making IOL insertion apparatus
WO2001007582A1 (en) * 1999-07-28 2001-02-01 Bio Quest Research, Ltd. Three-dimensional cell incubation media and method for incubating cells by using the same
US6248111B1 (en) 1999-08-06 2001-06-19 Allergan Sales, Inc. IOL insertion apparatus and methods for using same
US6283975B1 (en) 1996-07-10 2001-09-04 Allergan Sales, Inc. IOL insertion apparatus and method for making and using same
US6506895B2 (en) 1997-08-15 2003-01-14 Surmodics, Inc. Photoactivatable nucleic acids
EP1359864A1 (en) * 2001-01-29 2003-11-12 Icon Technologies, LLC Irradiated stent coating
DE10223310A1 (en) * 2002-05-24 2003-12-11 Biotronik Mess & Therapieg Process for coating implants with a polysaccharide layer
EP1453557A2 (en) * 2001-10-26 2004-09-08 Icon Technologies, LLC Improved stent coating
DE10329296A1 (en) * 2003-06-24 2005-01-27 Institut Für Polymerforschung Dresden E.V. Coating systems for blood-contacting medicinal materials, e.g. prostheses or heart valves, comprising synthetic blood coagulation inhibiting layer linked to biomaterial surface via flexible spacer layer
DE10330900A1 (en) * 2003-07-01 2005-01-27 Institut Für Polymerforschung Dresden E.V. Modular coating system for biomaterials
AU781125B2 (en) * 1997-04-04 2005-05-05 Board Of Regents Of The University Of Nebraska, The Methods and materials for making and using transgenic dicamba-degrading organisms
WO2006107336A1 (en) * 2005-04-06 2006-10-12 Surmodics, Inc. Bioactive coating compositions for medical devices
WO2006135910A1 (en) * 2005-06-13 2006-12-21 Innovative Surface Technologies, Llc Photochemical crosslinkers for polymer coatings and substrate tie-layer
WO2007012051A1 (en) * 2005-07-20 2007-01-25 Surmodics, Inc. Polymeric coatings and methods for cell attachment
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
US7348055B2 (en) 2001-12-21 2008-03-25 Surmodics, Inc. Reagent and method for providing coatings on surfaces
WO2010028104A1 (en) * 2008-09-05 2010-03-11 Innovative Surface Technologies, Inc. Photoactivatable crosslinker compositions for surface modification
US7812224B2 (en) 1997-04-04 2010-10-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
US8691983B2 (en) 2009-03-03 2014-04-08 Innovative Surface Technologies, Inc. Brush polymer coating by in situ polymerization from photoreactive surface
US8709809B2 (en) 2007-06-22 2014-04-29 Innovative Surface Technologies, Inc. Nanofibers containing latent reactive groups
US9034245B2 (en) 2010-03-04 2015-05-19 Icon Medical Corp. Method for forming a tubular medical device
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
US9116144B2 (en) 2007-06-22 2015-08-25 Innovative Surface Technologies, Inc. Methods for preparing thermally responsive cell culture surfaces
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion
US11779685B2 (en) 2014-06-24 2023-10-10 Mirus Llc Metal alloys for medical devices

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2066551C1 (en) * 1994-03-23 1996-09-20 Институт нефтехимического синтеза РАН Method of preparing insulin-containing polymeric hydrogel
AUPM771094A0 (en) * 1994-08-26 1994-09-22 Orphean Nominees Pty Ltd Food holder
US6004583A (en) * 1995-03-22 1999-12-21 Orex Pharmaceutical Development Corp. Protein-containing polymer composition for oral administration
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6782886B2 (en) 1995-04-05 2004-08-31 Aerogen, Inc. Metering pumps for an aerosolizer
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
AU720963B2 (en) * 1995-05-26 2000-06-15 Surmodics, Inc. Method and implantable article for promoting endothelialization
US5804318A (en) * 1995-10-26 1998-09-08 Corvita Corporation Lubricious hydrogel surface modification
US5714360A (en) * 1995-11-03 1998-02-03 Bsi Corporation Photoactivatable water soluble cross-linking agents containing an onium group
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5853744A (en) * 1996-08-20 1998-12-29 Regents Of The University Of Minnesota Solid-phase method for attaching a biomolecule to a substrate surface with a photoreactive crosslinking agent
US6800278B1 (en) 1996-10-28 2004-10-05 Ballard Medical Products, Inc. Inherently antimicrobial quaternary amine hydrogel wound dressings
US6039940A (en) * 1996-10-28 2000-03-21 Ballard Medical Products Inherently antimicrobial quaternary amine hydrogel wound dressings
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US6146771A (en) 1997-07-01 2000-11-14 Terumo Cardiovascular Systems Corporation Process for modifying surfaces using the reaction product of a water-insoluble polymer and a polyalkylene imine
US6762019B2 (en) 1997-09-30 2004-07-13 Surmodics, Inc. Epoxide polymer surfaces
US5858653A (en) * 1997-09-30 1999-01-12 Surmodics, Inc. Reagent and method for attaching target molecules to a surface
US6465178B2 (en) 1997-09-30 2002-10-15 Surmodics, Inc. Target molecule attachment to surfaces
DE19818360C2 (en) * 1998-04-24 2000-05-31 Suisse Electronique Microtech Dextran coated surface
ES2179646T3 (en) * 1998-04-27 2003-01-16 Surmodics Inc COATING THAT RELEASES A BIOACTIVE AGENT.
US20050147534A1 (en) * 1998-05-05 2005-07-07 Massachusetts Institute Of Technology Emissive sensors and devices incorporating these sensors
US8198096B2 (en) * 1998-05-05 2012-06-12 Massachusetts Institute Of Technology Emissive polymers and devices incorporating these polymers
DE69915466T2 (en) * 1998-05-05 2005-01-20 Massachusetts Institute Of Technology, Cambridge Light-emitting polymers and devices containing them
US8070796B2 (en) * 1998-07-27 2011-12-06 Icon Interventional Systems, Inc. Thrombosis inhibiting graft
US7967855B2 (en) 1998-07-27 2011-06-28 Icon Interventional Systems, Inc. Coated medical device
US6183516B1 (en) * 1998-10-08 2001-02-06 Sulzer Orthopedics Inc. Method for improved bonding of prosthetic devices to bone
US6514768B1 (en) * 1999-01-29 2003-02-04 Surmodics, Inc. Replicable probe array
US20030148360A1 (en) * 1999-01-29 2003-08-07 Surmodics, Inc. Replicable probe array
JP4505871B2 (en) * 1999-04-07 2010-07-21 株式会社ジェイ・エム・エス Blood flow contact medical member treated with antithrombotic mucopolysaccharide and method for producing the blood flow contact medical member
EP1168934B1 (en) * 1999-04-12 2008-02-13 Cornell Research Foundation, Inc. Hydrogel-forming system with hydrophobic and hydrophilic components
US6340465B1 (en) 1999-04-12 2002-01-22 Edwards Lifesciences Corp. Lubricious coatings for medical devices
US6716445B2 (en) * 1999-04-12 2004-04-06 Cornell Research Foundation, Inc. Hydrogel entrapping therapeutic agent and stent with coating comprising this
US6174683B1 (en) * 1999-04-26 2001-01-16 Biocept, Inc. Method of making biochips and the biochips resulting therefrom
US6372813B1 (en) 1999-06-25 2002-04-16 Motorola Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays
US6664061B2 (en) 1999-06-25 2003-12-16 Amersham Biosciences Ab Use and evaluation of a [2+2] photoaddition in immobilization of oligonucleotides on a three-dimensional hydrogel matrix
US6780980B1 (en) * 1999-06-30 2004-08-24 Centre Suisse D'electronique Et De Microtechnique S.A. Process for the modification of surface
US6309660B1 (en) 1999-07-28 2001-10-30 Edwards Lifesciences Corp. Universal biocompatible coating platform for medical devices
US6235177B1 (en) 1999-09-09 2001-05-22 Aerogen, Inc. Method for the construction of an aperture plate for dispensing liquid droplets
US7220276B1 (en) 2000-03-06 2007-05-22 Surmodics, Inc. Endovascular graft coatings
US6410643B1 (en) 2000-03-09 2002-06-25 Surmodics, Inc. Solid phase synthesis method and reagent
US7971588B2 (en) 2000-05-05 2011-07-05 Novartis Ag Methods and systems for operating an aerosol generator
US8336545B2 (en) 2000-05-05 2012-12-25 Novartis Pharma Ag Methods and systems for operating an aerosol generator
US6543443B1 (en) 2000-07-12 2003-04-08 Aerogen, Inc. Methods and devices for nebulizing fluids
EP1313785B1 (en) * 2000-08-21 2009-04-01 Massachusetts Institute Of Technology Composition comprising iptycene polymers with high internal volume
ES2189602B1 (en) * 2000-10-11 2004-08-01 Universidad De Murcia PROCEDURE FOR THE IMMOBILIZATION OF A BINDING ON A SUPPORT.
DE60033665T2 (en) * 2000-10-31 2007-10-31 Micronas Gmbh Patterned polymer surfaces suitable for bioconjugations and methods for their preparation
US6546927B2 (en) 2001-03-13 2003-04-15 Aerogen, Inc. Methods and apparatus for controlling piezoelectric vibration
US6550472B2 (en) 2001-03-16 2003-04-22 Aerogen, Inc. Devices and methods for nebulizing fluids using flow directors
CN1524180A (en) * 2001-04-10 2004-08-25 纽约市哥伦比亚大学信托人 Novel microarrays and methods of use thereof
US6732944B2 (en) 2001-05-02 2004-05-11 Aerogen, Inc. Base isolated nebulizing device and methods
US6554201B2 (en) 2001-05-02 2003-04-29 Aerogen, Inc. Insert molded aerosol generator and methods
US6444318B1 (en) 2001-07-17 2002-09-03 Surmodics, Inc. Self assembling monolayer compositions
US7195913B2 (en) * 2001-10-05 2007-03-27 Surmodics, Inc. Randomly ordered arrays and methods of making and using
US8158106B2 (en) * 2001-10-05 2012-04-17 Surmodics, Inc. Particle immobilized coatings and uses thereof
AU2002353997A1 (en) * 2001-11-01 2003-05-12 Rensselaer Polytechnic Institute In vitro metabolic engineering on microscale devices
US7462325B2 (en) * 2001-11-30 2008-12-09 Nomadics, Inc. Luminescent polymer particles
MXPA04006629A (en) 2002-01-07 2004-11-10 Aerogen Inc Devices and methods for nebulizing fluids for inhalation.
US7677467B2 (en) 2002-01-07 2010-03-16 Novartis Pharma Ag Methods and devices for aerosolizing medicament
EP1474196B1 (en) 2002-01-15 2016-08-17 Novartis AG Methods and systems for operating an aerosol generator
US20040033546A1 (en) 2002-04-10 2004-02-19 The Trustees Of Columbia University In The City Of New York Novel microarrays and methods of use thereof
ES2572770T3 (en) 2002-05-20 2016-06-02 Novartis Ag Apparatus for providing spray for medical treatment and methods
US7097850B2 (en) * 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
AU2003269913A1 (en) * 2002-07-15 2004-02-02 Massachusetts Institute Of Technology Emissive, high charge transport polymers
US8016881B2 (en) 2002-07-31 2011-09-13 Icon Interventional Systems, Inc. Sutures and surgical staples for anastamoses, wound closures, and surgical closures
ATE548097T1 (en) 2002-09-03 2012-03-15 Whatman Ltd POROUS COMPOSITE MEMBRANE AND PRODUCTION METHOD THEREOF
CA2500903A1 (en) * 2002-09-13 2004-03-25 Pall Corporation Preparation and use of mixed mode solid substrates for chromatography adsorbents and biochip arrays
US20060292701A1 (en) * 2002-09-13 2006-12-28 Ciphergen Biosystems Inc. Photocrosslinked hydrogel blend surface coatings
US7045366B2 (en) * 2003-09-12 2006-05-16 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
FR2848847B1 (en) * 2002-12-18 2005-10-14 Coletica COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION COMPRISING AN AQUEOUS INSOLUBLE ENZYME AND USES THEREOF
US7166451B1 (en) * 2003-02-24 2007-01-23 The Ohio State University Immobilization of enzyme on a fibrous matrix
US20040209360A1 (en) * 2003-04-18 2004-10-21 Keith Steven C. PVA-based polymer coating for cell culture
DE10328815A1 (en) * 2003-06-21 2005-01-05 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Coating system for implants to increase tissue compatibility
US8616195B2 (en) 2003-07-18 2013-12-31 Novartis Ag Nebuliser for the production of aerosolized medication
GB0319929D0 (en) * 2003-08-26 2003-09-24 Suisse Electronique Microtech Yarn and textile products
US7309593B2 (en) * 2003-10-01 2007-12-18 Surmodics, Inc. Attachment of molecules to surfaces
EP1735378A1 (en) * 2004-03-17 2006-12-27 Ciphergen Biosystems, Inc. Photocrosslinked hydrogel blend surface coatings
CA2560507C (en) * 2004-03-26 2011-08-16 Surmodics, Inc. Composition and method for preparing biocompatible surfaces
US7550443B2 (en) * 2004-03-26 2009-06-23 Surmodics, Inc. Process and systems for biocompatible surfaces
US20050244459A1 (en) 2004-04-06 2005-11-03 Dewitt David M Coating compositions for bioactive agents
US7946291B2 (en) 2004-04-20 2011-05-24 Novartis Ag Ventilation systems and methods employing aerosol generators
WO2005113034A1 (en) * 2004-05-12 2005-12-01 Surmodics, Inc. Natural biodegradable polysaccharides coatings for medical articles
US20050281857A1 (en) * 2004-05-25 2005-12-22 Heyer Toni M Methods and reagents for preparing biomolecule-containing coatings
WO2006002112A1 (en) * 2004-06-18 2006-01-05 Surmodics, Inc. Devices, articles, coatings, and methods for controlled active agent release
US8617819B2 (en) 2004-09-17 2013-12-31 Massachusetts Institute Of Technology Polymers for analyte detection
WO2006063181A1 (en) * 2004-12-06 2006-06-15 Surmodics, Inc. Multifunctional medical articles
WO2006084238A2 (en) * 2005-02-04 2006-08-10 Molecular Imaging Corporation Probe and method of making a probe using crosslinker compositions as chemical and biological sensors
WO2006096251A2 (en) 2005-03-03 2006-09-14 Icon Medical Corp. Improved metal alloys for medical device
WO2006110197A2 (en) 2005-03-03 2006-10-19 Icon Medical Corp. Polymer biodegradable medical device
US7540995B2 (en) 2005-03-03 2009-06-02 Icon Medical Corp. Process for forming an improved metal alloy stent
US20060200048A1 (en) * 2005-03-03 2006-09-07 Icon Medical Corp. Removable sheath for device protection
US8105666B2 (en) * 2005-03-15 2012-01-31 Finley Michael J Compliant polymeric coatings for insertable medical articles
AU2006249574B2 (en) 2005-05-25 2012-01-19 Novartis Ag Vibration systems and methods
US20070048759A1 (en) * 2005-06-10 2007-03-01 Dan Luo Detection of target molecules with labeled nucleic acid detection molecules
US8663673B2 (en) 2005-07-29 2014-03-04 Surmodics, Inc. Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility
US8486621B2 (en) * 2005-08-11 2013-07-16 Cornell Research Foundation, Inc. Nucleic acid-based matrixes
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
US20070148246A1 (en) * 2005-08-11 2007-06-28 Dan Luo Nucleic Acid-Based Matrixes
US20070048249A1 (en) 2005-08-24 2007-03-01 Purdue Research Foundation Hydrophilized bactericidal polymers
US8512736B2 (en) * 2005-09-21 2013-08-20 Surmodics, Inc. Coatings including natural biodegradable polysaccharides and uses thereof
DE602006011764D1 (en) * 2005-09-21 2010-03-04 Surmodics Inc IN SITU OCCLUSION COMPOSITIONS WITH NATURAL BIODEGRADABLE POLYSACCHARIDES
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
WO2008019086A2 (en) * 2006-08-04 2008-02-14 Massachusetts Institute Of Technology Detection of explosives, toxins and other compositions
DE102006037724A1 (en) * 2006-08-11 2008-02-14 Merck Patent Gmbh Use of ascorbic acid derivatives for the functionalization of matrices
US20080063627A1 (en) * 2006-09-12 2008-03-13 Surmodics, Inc. Tissue graft materials containing biocompatible agent and methods of making and using same
US20080075753A1 (en) * 2006-09-25 2008-03-27 Chappa Ralph A Multi-layered coatings and methods for controlling elution of active agents
WO2008042289A2 (en) 2006-09-29 2008-04-10 Massachusetts Institute Of Technology Polymer synthetic technique
US8802447B2 (en) 2006-10-05 2014-08-12 Massachusetts Institute Of Technology Emissive compositions with internal standard and related techniques
US20090215189A1 (en) * 2006-10-27 2009-08-27 Massachusetts Institute Of Technology Sensor of species including toxins and chemical warfare agents
US20090123519A1 (en) * 2007-11-12 2009-05-14 Surmodics, Inc. Swellable hydrogel matrix and methods
EP2296630A2 (en) * 2008-05-07 2011-03-23 SurModics, Inc. Delivery of nucleic acid complexes from particles
WO2010017264A2 (en) * 2008-08-05 2010-02-11 Cornell University Photo-crosslinked nucleic acid hydrogels
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
AU2010208381A1 (en) * 2009-01-28 2011-08-04 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
AU2010208305A1 (en) * 2009-01-28 2011-09-08 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2010088300A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
WO2010088261A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Binding-site modified lectins and uses thereof
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010107520A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2716502C (en) 2009-05-15 2015-06-16 Interface Biologics, Inc. Antithrombogenic hollow fiber membranes and filters
US20110144373A1 (en) * 2009-12-10 2011-06-16 Surmodics, Inc. Water-soluble degradable photo-crosslinker
JP5152212B2 (en) * 2010-01-30 2013-02-27 株式会社ジェイ・エム・エス Blood flow contact medical member and method of manufacturing the blood flow contact medical member
WO2011131222A1 (en) * 2010-04-19 2011-10-27 Invatec S.P.A. Photoactivated polymeric material and its use for the preparation of medical devices
JP2013538247A (en) 2010-06-29 2013-10-10 サーモディクス,インコーポレイティド Fluorinated polymer and lubricity coating
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012015681A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
WO2012015691A2 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
TWI669554B (en) 2010-07-30 2019-08-21 瑞士商諾華公司 Readily-usable silicone hydrogel contact lenses
US8722076B2 (en) 2010-09-30 2014-05-13 Surmodics, Inc. Photochrome- or near IR dye-coupled polymeric matrices for medical articles
US10315987B2 (en) 2010-12-13 2019-06-11 Surmodics, Inc. Photo-crosslinker
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US20120171769A1 (en) 2010-12-30 2012-07-05 Mcgonigle Joseph S Cell attachment coatings and methods
EP2731429A4 (en) * 2011-07-15 2015-03-04 Univ Georgia Compounds, methods of making, and methods of use
MY164605A (en) 2011-10-12 2018-01-30 Novartis Ag Method for making uv-absorbing ophthalmic lenses
EP2766498B1 (en) 2011-10-14 2019-06-19 President and Fellows of Harvard College Sequencing by structure assembly
US11021737B2 (en) 2011-12-22 2021-06-01 President And Fellows Of Harvard College Compositions and methods for analyte detection
EP4249605A3 (en) 2011-12-22 2023-11-15 President And Fellows Of Harvard College Methods for analyte detection
WO2013151991A1 (en) 2012-04-02 2013-10-10 Surmodics, Inc. Hydrophilic polymeric coatings for medical articles with visualization moiety
US9914967B2 (en) 2012-06-05 2018-03-13 President And Fellows Of Harvard College Spatial sequencing of nucleic acids using DNA origami probes
EP2866849B1 (en) 2012-06-29 2020-02-19 SurModics, Inc. Cell attachment coatings and methods using phosphorous-containing photoreagent
US9629945B2 (en) 2012-12-12 2017-04-25 Surmodics, Inc. Stilbene-based reactive compounds, polymeric matrices formed therefrom, and articles visualizable by fluorescence
CN104871036B (en) 2012-12-17 2019-12-10 诺华股份有限公司 Method for making improved UV-absorbing ophthalmic lenses
EP3578666A1 (en) 2013-03-12 2019-12-11 President and Fellows of Harvard College Method of generating a three-dimensional nucleic acid containing matrix
WO2015051052A2 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
EP3038521B1 (en) 2013-10-12 2019-05-01 Innovative Surface Technologies, Inc. Tissue scaffolds for electrically excitable cells
WO2015095157A1 (en) 2013-12-17 2015-06-25 Novartis Ag A silicone hydrogel lens with a crosslinked hydrophilic coating
US10179932B2 (en) 2014-07-11 2019-01-15 President And Fellows Of Harvard College Methods for high-throughput labelling and detection of biological features in situ using microscopy
JP2017527422A (en) 2014-08-15 2017-09-21 ザ・ジョンズ・ホプキンス・ユニバーシティー Composite materials for tissue repair
MY183678A (en) 2014-08-26 2021-03-08 Alcon Inc Method for applying stable coating on silicone hydrogel contact lenses
US10300175B2 (en) * 2014-09-12 2019-05-28 Heart Research Institute, Ltd. Medical devices with reduced thrombogenicity
FR3029784B1 (en) 2014-12-16 2016-12-30 Oreal COSMETIC PROCESS FOR ATTENUATING WRINKLES
EP4091639A1 (en) 2015-08-17 2022-11-23 The Johns Hopkins University In situ forming composite material for tissue restoration
JP6882282B2 (en) 2015-11-03 2021-06-02 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and equipment for stereoscopic imaging of three-dimensional nucleic acid-containing matrices
KR102604468B1 (en) 2015-12-15 2023-11-22 알콘 인코포레이티드 Method for applying stable coatings on silicone hydrogel contact lenses
EP3449016A4 (en) 2016-04-25 2019-10-02 President and Fellows of Harvard College Hybridization chain reaction methods for in situ molecular detection
WO2018045186A1 (en) 2016-08-31 2018-03-08 President And Fellows Of Harvard College Methods of combining the detection of biomolecules into a single assay using fluorescent in situ sequencing
JP7239465B2 (en) 2016-08-31 2023-03-14 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods for preparing nucleic acid sequence libraries for detection by fluorescence in situ sequencing
BR112019007896B1 (en) 2016-10-18 2022-11-08 Interface Biologics, Inc MIXED COMPOSITION, ARTICLE AND ITS PRODUCTION METHOD
CA3019250A1 (en) 2017-04-14 2019-10-13 President And Fellows Of Harvard College Methods for generation of cell-derived microfilament network
US11788123B2 (en) 2017-05-26 2023-10-17 President And Fellows Of Harvard College Systems and methods for high-throughput image-based screening
US20180340046A1 (en) 2017-05-27 2018-11-29 Poly Group LLC Dispersible antimicrobial complex and coatings therefrom
EP3638740A1 (en) 2017-06-16 2020-04-22 Poly Group LLC Polymeric antimicrobial surfactant
WO2019116142A1 (en) 2017-12-13 2019-06-20 Novartis Ag Method for producing mps-compatible water gradient contact lenses
EP3790601A1 (en) 2018-05-09 2021-03-17 The Johns Hopkins University Nanofiber-hydrogel composites for enhanced soft tissue replacement and regeneration
AU2019267711A1 (en) 2018-05-09 2020-12-03 The Johns Hopkins University Nanofiber-hydrogel composites for cell and tissue delivery
SG11202101934SA (en) * 2018-07-30 2021-03-30 Readcoor Llc Methods and systems for sample processing or analysis
US20230285641A1 (en) 2022-03-09 2023-09-14 Surmodics Coatings, LLC Thromboresistant coatings, coated devices, and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959078A (en) * 1973-05-18 1976-05-25 Midwest Research Institute Enzyme immobilization with a thermochemical-photochemical bifunctional agent
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US4722906A (en) * 1982-09-29 1988-02-02 Bio-Metric Systems, Inc. Binding reagents and methods
WO1990000887A1 (en) * 1988-07-22 1990-02-08 Bio-Metric Systems, Inc. Preparation of polymeric surfaces
US4979959A (en) * 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
WO1991016425A1 (en) * 1990-04-12 1991-10-31 Hans Sigrist Method for the light-induced immobilization of biomolecules on chemically 'inert' surfaces

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4007089A (en) * 1975-04-30 1977-02-08 Nelson Research & Development Company Method for binding biologically active compounds
DE3435744C2 (en) * 1984-09-28 1986-08-07 Organogen Medizinisch-Molekularbiologische Forschungsgesellschaft mbH, 6900 Heidelberg Carrier material for use in immune determinations
US5024742A (en) * 1988-02-24 1991-06-18 Cedars-Sinai Medical Center Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers
JPH02108489A (en) * 1988-10-17 1990-04-20 Fanuc Ltd Wrist mechanism for articulated laser robot
WO1991003990A1 (en) * 1989-09-15 1991-04-04 Chiron Ophthalmics, Inc. Method for achieving epithelialization of synthetic lenses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975350A (en) * 1972-08-02 1976-08-17 Princeton Polymer Laboratories, Incorporated Hydrophilic or hydrogel carrier systems such as coatings, body implants and other articles
US3959078A (en) * 1973-05-18 1976-05-25 Midwest Research Institute Enzyme immobilization with a thermochemical-photochemical bifunctional agent
US4722906A (en) * 1982-09-29 1988-02-02 Bio-Metric Systems, Inc. Binding reagents and methods
US4979959A (en) * 1986-10-17 1990-12-25 Bio-Metric Systems, Inc. Biocompatible coating for solid surfaces
WO1990000887A1 (en) * 1988-07-22 1990-02-08 Bio-Metric Systems, Inc. Preparation of polymeric surfaces
WO1991016425A1 (en) * 1990-04-12 1991-10-31 Hans Sigrist Method for the light-induced immobilization of biomolecules on chemically 'inert' surfaces

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018665A1 (en) * 1994-01-10 1995-07-13 Hemasure, Inc. Device and process for removing leukocytes and viral inactivating agents from blood
US5639376A (en) * 1994-01-10 1997-06-17 Hemasure, Inc. Process for simultaneously removing leukocytes and methylene blue from plasma
US5935436A (en) * 1994-01-10 1999-08-10 Hemasure Inc. Device for simultaneously removing leukocytes and methylene blue from plasma
US5817237A (en) * 1994-01-10 1998-10-06 Hemasure, Inc. Process for simultaneously removing leukocytes and methylene blue from plasma
WO1996022062A1 (en) * 1995-01-17 1996-07-25 Allergan Iol insertion apparatus and method for using same
US5803925A (en) * 1995-01-17 1998-09-08 Allergan IOL insertion apparatus with covalently bonded lubricant
US5916585A (en) * 1996-06-03 1999-06-29 Gore Enterprise Holdings, Inc. Materials and method for the immobilization of bioactive species onto biodegradable polymers
WO1997046267A1 (en) * 1996-06-03 1997-12-11 Gore Enterprise Holdings, Inc. Materials and methods for the immobilization of bioactive species onto biodegradable polymers
US6398788B1 (en) 1996-07-10 2002-06-04 Allergan Method for making and using IOL insertion apparatus
US5942277A (en) * 1996-07-10 1999-08-24 Allergan IOL insertion apparatus and method for making and using same
US6679891B2 (en) 1996-07-10 2004-01-20 Advanced Medical Optics, Inc. IOL insertion apparatus and method for making and using same
US6283975B1 (en) 1996-07-10 2001-09-04 Allergan Sales, Inc. IOL insertion apparatus and method for making and using same
AU781125B2 (en) * 1997-04-04 2005-05-05 Board Of Regents Of The University Of Nebraska, The Methods and materials for making and using transgenic dicamba-degrading organisms
US7812224B2 (en) 1997-04-04 2010-10-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
US8119380B2 (en) 1997-04-04 2012-02-21 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
US8629323B2 (en) 1997-04-04 2014-01-14 Board Of Regents Of The University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
US6083230A (en) * 1997-07-30 2000-07-04 Allergan Method for making IOL insertion apparatus
WO1999008717A3 (en) * 1997-08-15 1999-05-06 Surmodics Inc Latent reactive polymers with biologically active moieties
US6506895B2 (en) 1997-08-15 2003-01-14 Surmodics, Inc. Photoactivatable nucleic acids
US6514734B1 (en) 1997-08-15 2003-02-04 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and latent reactive moieties and bioactive groups
AU734759B2 (en) * 1997-08-15 2001-06-21 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6121027A (en) * 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
EP1577670A3 (en) * 1997-08-15 2005-12-07 SurModics, Inc. Latent reactive polymers with biologically active moieties
EP1577670A2 (en) * 1997-08-15 2005-09-21 SurModics, Inc. Latent reactive polymers with biologically active moieties
WO1999008717A2 (en) * 1997-08-15 1999-02-25 Surmodics, Inc. Latent reactive polymers with biologically active moieties
US6642050B1 (en) 1999-07-28 2003-11-04 Amcite Research, Ltd. Three-dimensional cell culture material having sugar polymer containing cell recognition sugar chain
WO2001007582A1 (en) * 1999-07-28 2001-02-01 Bio Quest Research, Ltd. Three-dimensional cell incubation media and method for incubating cells by using the same
US6248111B1 (en) 1999-08-06 2001-06-19 Allergan Sales, Inc. IOL insertion apparatus and methods for using same
EP1359864A4 (en) * 2001-01-29 2005-06-15 Icon Technologies Llc Irradiated stent coating
EP1359864A1 (en) * 2001-01-29 2003-11-12 Icon Technologies, LLC Irradiated stent coating
EP1453557A2 (en) * 2001-10-26 2004-09-08 Icon Technologies, LLC Improved stent coating
EP1453557A4 (en) * 2001-10-26 2005-07-13 Icon Technologies Llc Improved stent coating
US7348055B2 (en) 2001-12-21 2008-03-25 Surmodics, Inc. Reagent and method for providing coatings on surfaces
US8039524B2 (en) 2001-12-21 2011-10-18 Surmodics, Inc. Reagent and method for providing coatings on surfaces
US7736689B2 (en) 2001-12-21 2010-06-15 Surmodics, Inc. Reagent and method for providing coatings on surfaces
DE10223310A1 (en) * 2002-05-24 2003-12-11 Biotronik Mess & Therapieg Process for coating implants with a polysaccharide layer
DE10329296A1 (en) * 2003-06-24 2005-01-27 Institut Für Polymerforschung Dresden E.V. Coating systems for blood-contacting medicinal materials, e.g. prostheses or heart valves, comprising synthetic blood coagulation inhibiting layer linked to biomaterial surface via flexible spacer layer
DE10329296B4 (en) * 2003-06-24 2007-07-12 Leibniz-Institut Für Polymerforschung Dresden E.V. Coating system for biomaterials
DE10330900A1 (en) * 2003-07-01 2005-01-27 Institut Für Polymerforschung Dresden E.V. Modular coating system for biomaterials
DE10330900B4 (en) * 2003-07-01 2006-09-14 Leibniz-Institut Für Polymerforschung Dresden E.V. Biomaterial with a modular coating system for use in direct blood contact medical devices
US9107899B2 (en) 2005-03-03 2015-08-18 Icon Medical Corporation Metal alloys for medical devices
WO2006107336A1 (en) * 2005-04-06 2006-10-12 Surmodics, Inc. Bioactive coating compositions for medical devices
US7772393B2 (en) 2005-06-13 2010-08-10 Innovative Surface Technologies, Inc. Photochemical crosslinkers for polymer coatings and substrate tie-layer
US8779206B2 (en) 2005-06-13 2014-07-15 Innovative Surface Technologies, Llc Photochemical crosslinkers for polymer coatings and substrate tie-layer
WO2006135910A1 (en) * 2005-06-13 2006-12-21 Innovative Surface Technologies, Llc Photochemical crosslinkers for polymer coatings and substrate tie-layer
US8487137B2 (en) 2005-06-13 2013-07-16 Innovative Surface Technologies, Llc Photochemical crosslinkers for polymer coatings and substrate tie-layer
WO2007012051A1 (en) * 2005-07-20 2007-01-25 Surmodics, Inc. Polymeric coatings and methods for cell attachment
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
US8709809B2 (en) 2007-06-22 2014-04-29 Innovative Surface Technologies, Inc. Nanofibers containing latent reactive groups
US9116144B2 (en) 2007-06-22 2015-08-25 Innovative Surface Technologies, Inc. Methods for preparing thermally responsive cell culture surfaces
WO2010028104A1 (en) * 2008-09-05 2010-03-11 Innovative Surface Technologies, Inc. Photoactivatable crosslinker compositions for surface modification
US9809713B2 (en) 2008-09-05 2017-11-07 Innovation Surface Technologies, Inc. Photoactivatable crosslinker compositions for surface modification
US8691983B2 (en) 2009-03-03 2014-04-08 Innovative Surface Technologies, Inc. Brush polymer coating by in situ polymerization from photoreactive surface
US9034245B2 (en) 2010-03-04 2015-05-19 Icon Medical Corp. Method for forming a tubular medical device
US11779685B2 (en) 2014-06-24 2023-10-10 Mirus Llc Metal alloys for medical devices
US11766506B2 (en) 2016-03-04 2023-09-26 Mirus Llc Stent device for spinal fusion

Also Published As

Publication number Publication date
EP0585436A1 (en) 1994-03-09
CA2107683A1 (en) 1993-08-14
US5563056A (en) 1996-10-08
ATE192487T1 (en) 2000-05-15
DE69328523T2 (en) 2000-09-21
EP0585436B1 (en) 2000-05-03
ES2145044T3 (en) 2000-07-01
EP0585436A4 (en) 1994-03-30
JP3455217B2 (en) 2003-10-14
DE69328523D1 (en) 2000-06-08
JPH06506959A (en) 1994-08-04
CA2107683C (en) 2004-07-20
AU1482797A (en) 1997-06-26
AU716543B2 (en) 2000-02-24
AU3664693A (en) 1993-09-03

Similar Documents

Publication Publication Date Title
US5563056A (en) Preparation of crosslinked matrices containing covalently immobilized chemical species and unbound releasable chemical species
Higuchi et al. Chemically modified polysulfone hollow fibers with vinylpyrrolidone having improved blood compatibility
US5837377A (en) Biomedical articles with ionically bonded polyelectrolyte coatings
US5741551A (en) Preparation of polymeric surfaces
US5002582A (en) Preparation of polymeric surfaces via covalently attaching polymers
EP0425485B1 (en) Preparation of polymeric surfaces
US6509098B1 (en) Poly(ethylene oxide) coated surfaces
JP4948740B2 (en) Method for surface modification of substrate and modified substrate obtained therefrom
US4743258A (en) Polymer materials for vascular prostheses
CA2625638C (en) Ultra-thin photo-polymer coatings and uses thereof
EP0397130B1 (en) Medical device having highly biocompatible surface and method for manufacturing the same
Kulik et al. In vitro platelet adhesion to nonionic and ionic hydrogels with different water contents
EP1020495B1 (en) Ion complex, coating material, and coating method
JPH064713B2 (en) Biocompatible material
Kamath et al. Surface modification of polymeric biomaterials by albumin grafting using γ‐irradiation
JP4033514B2 (en) Soluble cellulose derivatives and uses
JP2004357826A (en) Medical instrument
Iwasaki et al. Importance of a biofouling-resistant phospholipid polymer to create a heparinized blood-compatible surface
CA1340345C (en) Preparation of polymeric surfaces
Ishihara The role of water in the surface properties of phosphorlipid polymers
Ishihara Supramolecular Surfaces
JPH06287335A (en) Hydrogel and its production

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2107683

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993905897

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993905897

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993905897

Country of ref document: EP